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Preamble
Guidelines and position papers written under the auspices of the
ESC Committee for Practice Guidelines (CPG) summarize and
evaluate all available evidence on a particular issue at the time of
the writing process, with the aim of assisting health professionals
in selecting the best management strategies for an individual patient
with a given condition, taking into account the impact on outcome,
as well as the risk–benefit ratio of particular diagnostic or thera-
peutic means. CPG Guidelines and position papers should help
health professionals to make decisions in their daily practice. How-
ever, the final decisions concerning an individual patient must be
made by the responsible health professional(s) in consultation
with the patient and caregiver as appropriate.
Members of this Task Force were selected by the ESC to re-
present professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a com-
prehensive review of the published evidence for management (in-
cluding diagnosis, treatment, prevention and rehabilitation) of a
given condition according to CPG policy. A critical evaluation of
diagnostic and therapeutic procedures was performed, including as-
sessment of the risk–benefit ratio. Estimates of expected health
outcomes for larger populations were included, where data exist.
The experts of the writing and reviewing panels provided declara-
tions of interest forms for all relationships that might be perceived
as real or potential sources of conflicts of interest. These forms
were compiled into one file and can be found on the ESC website
(http://www.escardio.org/guidelines). Any changes in declarations of
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interest that arise during the writing period must be notified to
the ESC and updated. The Task Force received its entire financial
support from the ESC without any involvement from the healthcare
industry.
The ESC CPG supervises and coordinates the preparation of
new guidelines and position papers produced by task forces, expert
groups or consensus panels. The Committee is also responsible for
the endorsement process of these documents. The CPG docu-
ments undergo extensive review by the CPG and external experts.
After appropriate revisions these documents are approved by all the
experts involved in the Task Force. The finalized document is ap-
proved by the CPG for publication in the European Heart Journal.
The CPG documents were developed after careful consideration
of the scientific and medical knowledge and the evidence available
at the time of their dating.
The task of developing CPG documents covers not only integra-
tion of the most recent research, but also the creation of education-
al tools and implementation programmes for the recommendations.
To implement these documents, condensed pocket guidelines
versions, summary slides and an electronic version for digital appli-
cations (smartphones, etc.) are produced as well as other educa-
tional tools depending on the topic. These versions are abridged
and thus, if needed, one should always refer to the full text version,
which is freely available on the ESC website. The National Cardiac
Societies of the ESC are encouraged to endorse, translate and im-
plement all CPG documents (guidelines and position papers). Imple-
mentation programmes are needed because it has been shown that
the outcome of disease may be favourably influenced by the thor-
ough application of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the CPG Guidelines
and Position Papers fully into account when exercising their clinical
judgment, as well as in the determination and the implementation of
preventive, diagnostic or therapeutic medical strategies. However,
these CPG documents do not override in any way whatsoever
the individual responsibility of health professionals to make appro-
priate and accurate decisions in consideration of each patient’s
health condition and in consultation with that patient and the pa-
tient’s caregiver where appropriate and/or necessary. It is also the
health professional’s responsibility to verify the rules and regulations
applicable to drugs and devices at the time of prescription.
1. Introduction
Advances in treatment have led to improved survival of patients
with cancer, but have also increased morbidity and mortality due
to treatment side effects.1,2 Cardiovascular diseases (CVDs) are
one of the most frequent of these side effects, and there is a growing
concern that they may lead to premature morbidity and death
among cancer survivors.3 This may be the result of cardiotoxicity,
which involves direct effects of the cancer treatment on heart func-
tion and structure, or may be due to accelerated development of
CVD, especially in the presence of traditional cardiovascular risk
factors.4
Although the field of cardio-oncology has received increasing at-
tention in recent years, many aspects of both radiation-induced and
cancer drug– induced CVD are still to be fully elucidated. Further-
more, the inability to predict the long-term consequences of cancer
treatment–associated cardiovascular side effects leads to under- or
overdiagnosis of CVD, sometimes resulting in the failure to prevent
adverse events and sometimes to inappropriate interruption of a
potentially lifesaving cancer treatment.
The complex issue of CVD as a consequence of previous cancer
treatment requires the creation of multidisciplinary teams involving
specialists in cardiology, oncology and other related fields. The mu-
tual interest to provide optimal care for patients with cancer and
cancer survivors is an important motivation for the development
of cardio-oncology teams. However, the extent of care and the
interaction between the disciplines involved has not yet been de-
fined. The complexity of the clinical questions to be addressed by
cardio-oncologists will require the definition of a curriculum de-
scribing the necessary knowledge and skills to deliver optimal care
and the hospital setting in which these experts will be active. These
cardio-oncology teams should also be involved in the long-term sur-
veillance of cancer survivors with a potential for late-onset cardio-
vascular complications and in the development of potential new
treatments that may have cardiotoxic effects, as well as in the evalu-
ation of cardiac events related to such drugs.
This document reviews the different steps in cardiovascular mon-
itoring and decision-making before, during and after cancer treat-
ment with potential cardiovascular side effects. Although this
document is not a formal clinical practice guideline, it aims to assist
professionals involved in the treatment of patients with cancer and
survivors by providing an expert consensus regarding current stan-
dards of care for these individuals.
In general, the cardiovascular complications of cancer therapy can
be divided into nine main categories, which are discussed in this
document:
† myocardial dysfunction and heart failure (HF);
† coronary artery disease (CAD);
† valvular disease;
† arrhythmias, especially those induced by QT-prolonging drugs;
† arterial hypertension;
† thromboembolic disease;
† peripheral vascular disease and stroke;
† pulmonary hypertension and
† pericardial complications.
2. Cardiovascular complications
of cancer therapy: pathophysiology
and management
2.1 Myocardial dysfunction and heart
failure
2.1.1 Pathophysiology and clinical presentation
Myocardial dysfunction and HF, frequently described as cardiotoxi-
city, are the most concerning cardiovascular complications of cancer
therapies and cause an increase in morbidity and mortality. A collab-
orative effort among specialists involved in the treatment of patients
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with cancer is critical to prevent and manage cardiotoxicity while
not compromising cancer care, to maximize the patient’s overall
outcome.5 The time point when cardiotoxicity becomes clinically
manifest varies substantially; some cancer treatments induce side ef-
fects that appear early after exposure—and therefore may adversely
affect oncological therapy—while others generate cardiac injuries re-
sulting in clinical problems only years later. In addition, some cancer
drugs, for example, anthracyclines, can induce progressive cardiac re-
modelling as a late consequence of earlier myocyte damage, resulting
in late cardiomyopathy, while others may cause transient cardiac dys-
function without long-term consequences.
The prediction of long-term cardiovascular prognosis is frequent-
ly challenging because patients with cancer typically receive multiple
cancer drugs and sometimes radiation, with the potential for cardi-
otoxic effects from interactions among the different therapeutic
modalities.6
Left ventricular (LV) dysfunction and HF are relatively common
and serious side effects of cancer treatment. Survivors of paediatric
cancer, treated with anthracyclines and/or mediastinal radiotherapy,
have a 15-fold increased lifetime risk for HF comparedwith matched
controls.7 In older patients with pre-existing cardiovascular risk, the
short-term risk for developing HF is also increased. For example,
survivors of aggressive non-Hodgkin lymphoma have a 17% inci-
dence of clinical HF at 5 years.8 There is also growing awareness
of the occurrence of LV dysfunction or HF caused by tyrosine kinase
inhibitors (TKIs), particularly in cancer patients with pre-existing
cardiovascular risk factors.9 Table 1 provides an overview of the in-
cidence of LV dysfunction with different chemotherapeutic drugs.
2.1.1.1 Anthracyclines
Anthracyclines have high efficacy for treatment of solid tumours and
haematological malignancies, and avoiding their use due to concerns
about cardiac side effects may negatively impact prognosis.22,23 On
the other hand, anthracyclines may cause irreversible cardiac dam-
age, which in turn affects prognosis.24 For example, doxorubicin is
associated with a 5% incidence of congestive HF when a cumulative
lifetime dose of 400 mg/m2 is reached, and higher doses lead to an
exponential increase in risk, up to 48% at 700 mg/m2.10 However,
there is considerable variability among patients in their susceptibility
to anthracyclines. While many tolerate standard-dose anthracy-
clines without long-term complications, treatment-related cardio-
toxicity may occur as early as after the first dose in other patients.25
The most commonly accepted pathophysiological mechanism of
anthracycline-induced cardiotoxicity is the oxidative stress hypoth-
esis, which suggests that the generation of reactive oxygen species
and lipid peroxidation of the cell membrane damage cardiomyo-
cytes. Other mechanisms have been suggested to play a role.26–31
For a detailed discussion of the cellular and molecular mechanisms,
the reader is referred to two reviews.32,33
The cardiotoxicity of anthracyclines may be acute, early or late.
Acute toxicity, predominantly supraventricular arrhythmia, transi-
ent LV dysfunction and electrocardiographic (ECG) changes, devel-
ops in ,1% of patients immediately after infusion and is usually
reversible. However, acute cardiac dysfunction may also reflect
myocyte injury that eventually can evolve into early or late cardio-
toxicity. There are no proven strategies to identify if cardiac dysfunc-
tion is reversible or progressive; however, elevation of cardiac
biomarkers may be a way to identify patients at risk for long-term
cardiotoxicity.
Early effects occur within the first year of treatment, while late
effects manifest themselves after several years (median of 7 years after
treatment).34,35 In patients treated with commonly used anthracycline
doses and .65 years of age, the rate of anthracycline-associated HF
Table 1 Incidence of left ventricular dysfunction
associated with chemotherapy drugs10 – 21
Chemotherapy agents Incidence (%)
Anthracyclines (dose dependent)
Doxorubicin (Adriamycin)
400 mg/m2
550 mg/m2
700 mg/m2
3–5
7–26
18–48
Idarubicin (>90 mg/m2) 5–18
Epirubicin  (>900 mg/m2) 0.9–11.4
Mitoxanthone >120 mg/m2 2.6
Liposomal anthracyclines (>900 mg/m2) 2
Alkylating agents
Cyclophosphamide 7–28
Ifosfamide 
<10 g/m2  
12.5–16 g/m2  
0.5
17
Antimetabolites
Clofarabine 27
Antimicrotubule agents
Docetaxel 2.3–13
Paclitaxel <1
Monoclonal antibodies
Trastuzumab 1.7–20.128a
Bevacizumab 1.6–414b
Pertuzumab 0.7–1.2
Small molecule tyrosine kinase inhibitors
Sunitinib 2.7–19
Pazopanib 7–11
Sorafenib 4–8
Dasatinib 2–4
Imatinib mesylate 0.2–2.7
Lapatinib 0.2–1.5
Nilotinib 1
Proteasome inhibitors
11–25
Bortezomib 2–5
Miscellanous
Everolimus <1
Temsirolimus <1
Carfilzomib
aWhen used in combination with anthracyclines and cyclophosphamide.
bIn patients receiving concurrent anthracyclines.
ESC CPG Position Paper Page 5 of 34
 by guest on A
ugust 31, 2016
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
can be as high as 10%.10 This classification (early and late) is based on
retrospective studies in which the LV ejection fraction (LVEF) decline
was determined either after HF development or on random evalua-
tions in paediatric patients with cancer. A recent study by Cardinale
et al.,36 involving 2625 patients (mean follow-up 5.2 years), showed
a 9% overall incidence of cardiotoxicity after anthracycline treatment,
and 98% of cases occurred within the first year and were asymptom-
atic. Anthracycline-induced cardiotoxicity is most likely a phenom-
enon characterized by continuous progressive decline in LVEF. Many
affected patients may initially be asymptomatic, with clinical manifesta-
tions appearing years later, often in the context of other triggering fac-
tors, which may indicate that anthracyclines negatively affect
compensatory mechanisms.37
Furthermore, if anthracycline-associated cardiac dysfunction is
detected early and treated with HF medications, patients frequently
have a good functional recovery. Conversely, if patients are identi-
fied late after the onset of cardiac dysfunction, HF is typically difficult
to treat.38 Risk factors for anthracycline-related cardiotoxicity in-
clude lifetime cumulative dose, infusion regimen and any condition
that increases cardiac susceptibility, including pre-existing cardiac
disease, hypertension, concomitant use of other chemotherapies
or mediastinal radiation therapy and older age (.65 years).13
The developing heart is also particularly vulnerable, and paediatric
patients treated with anthracyclines are at an exceedingly high
risk for anthracycline cardiotoxicity39 (Table 2). In patients with
one or multiple risk factors for anthracycline cardiotoxicity, the cu-
mulative dose vs. cardiotoxicity curve is shifted to the left and these
patients should be monitored carefully or alternative chemothera-
peutics considered.
2.1.1.2 Other conventional chemotherapies
Other conventional chemotherapies that can induce myocardial
dysfunction and HF are cyclophosphamide, cisplatin, ifosfamide
and taxanes (paclitaxel and docetaxel). Cyclophosphamide cardio-
toxicity is relatively rare and is primarily seen in patients receiving
high doses (.140 mg/kg) before bone marrow transplantation.40
HF typically occurs within days of drug administration, and risk
factors include total bolus dose, older age, combination therapy
with other cancer drugs and mediastinal irradiation.41 Some alkylat-
ing agents similar to cyclophosphamide, such as cisplatin and ifosfa-
mide, infrequently cause HF due to several pathological effects,
including myocardial ischaemia. Additionally, platin-containing
chemotherapy requires the administration of a high intravenous vol-
ume to avoid platin-related toxicity. This volume overload in pa-
tients with pre-existing myocardial impairment, rather than the
direct toxicity of these drugs, is often the cause of first or recurrent
episodes of HF. Docetaxel, a drug frequently used in breast cancer,
in combination with or after anthracyclines, cyclophosphamide or
trastuzumab, also appears to increase the incidence of HF; however,
the contribution of individual agents in multidrug schemes is fre-
quently difficult to assess.42 Some reports suggest that taxanes
may be safer in patients with pre-existing LV dysfunction, in whom
anthracyclines should be avoided,43 but the absolute cardiotoxic
risks with taxanes are unknown. However, there is considerable de-
bate with regard to patients with breast cancer for whom the true
benefits of using anthracyclines vs. taxanes is not as clear as it is for
tumours such as lymphomas or sarcomas. The risk–benefit assess-
ment should encompass both the risk factors of the individual pa-
tient and the potential efficacy based on the characteristics of the
tumour.
2.1.1.3 Immunotherapies and targeted therapies
More recently, immunotherapies and targeted therapies have led
to substantial improvement in the efficacy of cancer drugs.
Inhibition of human epidermal growth factor receptor 2 (HER2)
signalling with either antibodies [trastuzumab, pertuzumab,
trastuzumab-emtansine (T-DM1)] or TKIs (lapatinib) have improved
outcomes of patients with HER2-positive breast cancer when used
in conjunction with chemotherapies.44 Initially, cardiotoxicity was
high when trastuzumab was given concomitantly with anthracyclines
in a trial of metastatic breast cancer.45 Applying trastuzumab after
anthracyclines, or using an anthracycline-free chemotherapy regi-
men, substantially reduced the rate of clinical HF. Based on several
large-scale trials of adjuvant therapy in breast cancer, all of which
prospectively assessed cardiac side effects, the rate of cardiac dys-
function ranged from 7 to 34%, with HF [New York Heart Associ-
ation (NYHA) class III or IV] rates between 0 and 4%. The relative
risks for cardiac dysfunction and HF were 5.1 and 1.8, respectively.44
When trastuzumab was used concomitantly with antimetabolites
and alkylating agents in patients with gastric cancer, the rates of car-
diac dysfunction and HF were 5% and ,1%, respectively.46 These
data indicate that concomitant or previous use of anthracyclines
substantially increases the cardiotoxicity of trastuzumab. However,
in the aforementioned trials, patients were relatively young (median
age in the 50s) and had a normal or nearly normal cardiac function
(usually LVEF ≥50%) without significant prior cardiac disease. The
risk of trastuzumab cardiotoxicity in patients with pre-existing car-
diac conditions is unknown. This may also explain why some inves-
tigators found higher rates of cardiac side effects in registries. In a
retrospective observational study based on the International Classi-
fication of Diseases codes (without access to LVEF data), the cumu-
lative incidence of the composite of cardiac dysfunction or HF in
patients treated with anthracyclines and trastuzumab was 6.2%
and 20.1% after 1 and 5 years, respectively.47 A similar increase
Table 2 Factors associated with risk of cardiotoxicity
following treatment with anthracyclinesa
Risk factors
• Cumulative dose
• Female sex
• Age 
   - >65 years old
   - Paediatric population (<18 years)
• Renal failure
• Concomitant or previous radiation therapy involving the heart
• Concomitant chemotherapy
   - alkylating or antimicrotubule agents
 - immuno- and targeted therapies
• Pre-existing conditions
   - Cardiac diseases associating increased wall stress 
   - Arterial hypertension
   - Genetic factors
aAnthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin) or
anthracenedione (mitoxantrone).
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over time in cardiotoxicity was not seen in the trials of trastuzumab
as adjuvant therapy in breast cancer; indeed, a low risk for new-
onset cardiotoxicity after completion of trastuzumab therapy was
found.48–51 Long-term follow-up (up to 10 years) data are reassur-
ing in terms of the absence of late-onset HF in patients with low
baseline cardiovascular risk treated with trastuzumab.48–51 In con-
trast to anthracyclines, trastuzumab cardiotoxicity typically mani-
fests during treatment. This has led to the implementation of
different cardiotoxicity surveillance protocols that vary across
countries and centres. Generally, trastuzumab-associated cardio-
toxicity is not believed to be cumulative-dose related, although
twice the rate of LV dysfunction was reported when patients
were treated for 24 rather than the usual 12 months.49
Trastuzumab-induced LV dysfunction and HF are usually reversible
with trastuzumab interruption and/or treatment with HF therap-
ies.52 The mechanism of anti-HER2 drug-induced cardiotoxicity in-
cludes structural and functional changes in contractile proteins and
mitochondria, but it rarely leads to cell death, explaining the poten-
tial for reversibility.53,54 Risk factors for anti-HER2 drug-induced
cardiotoxicity include previous exposure to anthracyclines, short
time (3 weeks vs. 3 months) between anthracycline and anti-HER2
treatment, pre-existing arterial hypertension, low LVEF and older
age.3,55 One of the most relevant clinical implications of
trastuzumab-induced cardiotoxicity is treatment interruption,
which is associated with an increase in cancer recurrence.56 In pa-
tients with HER2-positive breast cancer receiving adjuvant trastuzu-
mab, cardiotoxicity was the most common reason for treatment
interruption in 13.5% of patients (30% for HF and 70% for asymp-
tomatic LVEF decline). In most trastuzumab breast cancer registra-
tion trials, treatment was stopped when patients developed HF or
(in asymptomatic patients) when LVEF dropped below 45%.52 There
are no randomized trials to prove that HF drugs will improve cardiac
function in patients with trastuzumab-associated cardiac dysfunc-
tion. However, analogous to the experience in patients with anthra-
cycline cardiotoxicity, trastuzumab-associated cardiac dysfunction is
likely to improve when these patients are treated with angiotensin-
converting enzyme (ACE) inhibitors.36,38
The cardiotoxicity risk of other anti-HER2-targeted therapies (la-
patinib, pertuzumab and T-DM1) appears similar to that of trastuzu-
mab. In a large trial of breast cancer patients comparing the efficacy
of adjuvant trastuzumab alone vs. trastuzumab and adjuvant lapati-
nib in .8000 women with a median follow-up of 4.5 years, the in-
cidence of cardiotoxicity ranged from 2 to 5%, and 2 to 3% of
women experienced HF.57 In this trial, where cardiac function was
assessed prospectively and compared with that at baseline, modern
schemes of adjuvant or neoadjuvant chemotherapy were used, in-
cluding anthracyclines in .70% of patients. The cardiotoxicity risk
for T-DM1 and pertuzumab also appear similar to trastuzumab, al-
though prospective data from large adjuvant trials are not yet
available.58,59
2.1.1.4 Inhibition of the vascular endothelial growth factor signalling
pathway
Inhibition of the vascular endothelial growth factor (VEGF) signalling
pathway benefits patients diagnosed with one of several different
solid cancers, but some of the VEGF inhibitors can cause reversible
or irreversible cardiac side effects, particularly when used with or
after conventional chemotherapies. In a large trial of patients with
breast cancer, where cardiac function was prospectively assessed,
the anti-VEGF antibody bevacizumab used after chemotherapy in-
duced LV dysfunction in 2% of patients and HF (NYHA III or IV)
in 1% of patients.60 Similarly, cardiotoxicity was found for the
TKIs sunitinib, pazopanib and axitinib. These drugs induce cardiac
dysfunction in 3–15% of patients and symptomatic HF in 1–10%
of patients.61–64 Other anti-VEGF inhibitors such as sorafenib and
vandetanib also induce cardiac dysfunction, but prospective data
from large clinical trials are missing. A recent meta-analysis evalu-
ated the risk of congestive HF associated with all US Food and
Drug Administration–approved VEGF receptor TKIs. A total of
10 647 patients from 21 randomized phase II and III trials using ap-
proved VEGF receptor TKIs (sunitinib, sorafenib, pazopanib, axiti-
nib, vandetanib, cabozantinib, ponatinib and regorafenib) were
included. A significant 2.69-fold increase in the risk of all grades of
congestive HF was observed with VEGF receptor TKIs compared
with controls not receiving TKIs. However, the risk of severe HF
was not significantly increased. The risk of relatively specific TKIs
(axitinib) was similar to relatively non-specific TKIs (sunitinib, sora-
fenib, vandetanib and pazopanib).65
VEGF inhibitors also cause substantial arterial hypertension, po-
tentially affecting cardiac function.66 Many anti-VEGF cancer drugs
inhibit multiple signalling pathways, and identification of the patho-
physiological mechanism causing cardiotoxicity can be challenging
(see Table 3 and section 2.5).67,68 The prognosis of patients experi-
encing cardiotoxicity with these drugs is difficult to assess accurate-
ly, as most of these compounds are used in patients with metastatic
disease with limited life expectancy. However, one can speculate
that if hypertension is controlled throughout therapy, some poten-
tial HF may be reduced. Similarly, if cardiac dysfunction develops, it
can be reversible in a large number of patients with appropriate and
intensive HF medication.69
2.1.1.5 Inhibition of BCR-ABL kinase
The inhibition of BCR-ABL kinase by small molecules such as imati-
nib has profoundly improved the prognosis of patients with several
forms of chronic leukaemia and some forms of gastrointestinal stro-
mal tumours. Although initial reports suggested a risk for
imatinib-induced cardiotoxicity, analysis of large cohorts did not
confirm these data.73 Newer, more potent inhibitors of BCR-ABL,
such as nilotinib and ponatinib, have also demonstrated an associ-
ation with cardiovascular events.74,75
2.1.1.6 Proteasome inhibitors
Proteasome inhibitors are a relatively new line of treatment for mul-
tiple myeloma. Bortezomib and carfilzomib are the two clinically
available drugs potentially causing cardiac dysfunction. Proteasomes,
protein complexes responsible for degrading dysfunctional or un-
needed proteins, have an important maintenance function in the
cardiomyocyte, and cardiac dysfunction and other cardiac issues
may be expected if this maintenance function is impaired.76 The in-
cidence of HF under bortezomib is relatively low (up to 4%) com-
pared with carfilzomib, although it is sometimes aggravated by the
concomitant use of steroids.77 Carfilzomib is a more potent and ir-
reversible proteosomal inhibitor, and preliminary data suggest a
substantially higher risk of HF (up to 25%).78,79
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2.1.1.7 Radiotherapy
The actual incidence of radiation-induced cardiotoxicity is difficult
to evaluate for several reasons. These include the long delay be-
tween exposure and clinical manifestation of heart disease, the
use of concomitant cardiotoxic chemotherapy, continuous im-
provements in radiation techniques and changes in the treated
population and failure to attribute cardiac disease to previous radio-
therapy despite increasing awareness of cardiovascular physicians of
its long-term side effects. Some studies found a relative risk of fatal
cardiovascular events between 2.2 and 12.7 in survivors of Hodgkin
lymphoma and between 1 and 2.2 in patients with breast cancer.80,81
The absolute excess risk ofmortality ranges from9.3 to 28 per 10 000
person-years of follow-up.80 Among survivors, the risk of HF was
increased 4.9-fold.81 In patients with breast cancer treated in the
era 1980–2000, the risk of cardiotoxicity was highest in patients
treated with both left breast radiotherapy and cardiotoxic chemo-
therapy, suggesting a synergistic effect on cardiac risk.82 Marked
interstitial myocardial fibrosis is common in radiotherapy-induced
cardiotoxicity, with lesions of variable volumes and distribution.80
In 1820 adult survivors of childhood cancer (median age 31 years;
median time from diagnosis 23 years) exposed to anthracycline
chemotherapy (n ¼ 1050), chest-directed radiotherapy (n ¼ 306)
or both (n ¼ 464), 22% of survivors exposed to radiotherapy alone
had evidence of diastolic dysfunction and 27.4% showed reduced
exercise capacity (,490 m 6-min walk).83 Systolic dysfunction is
generally observed when radiotherapy is combined with anthracy-
clines. HF may also be aggravated by concomitant radiation-induced
valvular heart disease (VHD) and CAD, and can evolve over years.
2.1.2 Diagnostic and therapeutic management
2.1.2.1 Screening, risk stratification and early detection strategies
The first step to identify patients at increased risk for cardiotoxicity
consists of a careful baseline assessment of cardiovascular risk factors
(Table 4). A limited number of studies have generated risk scores for
different oncology patient cohorts.39,84 However, none of these risk
scores has been validated prospectively, and clinical judgement is re-
quired when evaluating the risk at an individual level. Risk assessment
should include clinical history and examination and baseline measure-
ment of cardiac function. Cardiac biomarkers (natriuretic peptides or
troponins) may be considered in addition, preferably using the same
assay that will be used during follow-up measurements, to increase
comparability. It is critical to detect subclinical cardiac abnormalities,
which may influence clinical decisions regarding the choice of chemo-
therapy, indication for cardioprotection or increased surveillance
frequency (e.g. asymptomatic LV dysfunction). Finally, baseline assess-
ment of cardiovascular risk factors allows appropriate interpretation
of subsequent results/changes during regularmonitoring. Baseline risk
Table 3 Factors associated with risk of cardiotoxicity
following anti-HER2 compounds and VEGF
inhibitors70 –72
Agent Risk factors
Anti-HER2 compounds
- Antibodies
  - Trastuzumab
  - Pertuzumab
  - T-DM1 
- Tyrosine kinase inhibitor
  - Lapatinib
• Previous or concomitant 
 anthracycline treatment (short time 
 between anthracycline and anti-HER2 
 treatment)
• Age (>65 years)
• High BMI >30 kg/mg2
• Previous LV dysfunction
• Arterial hypertension
• Previous radiation therapy
VEGF inhibitors
- Antibodies
  - Bevacizumab
  - Ramucirumab
 or left side VHD (e.g. mitral  
 regurgitation), chronic ischaemic 
 cardiomyopathy
• Previous anthracycline
- Tyrosine kinase inhibitors
  - Sunitinib
  - Pazopanib
  - Axitinib
  - Neratinib
  - Afatinib
  - Sorafenib
  - Dasatinib
• Arterial hypertension
• Pre-existing cardiac disease  
Pre-existing HF, significant CAD
BMI ¼ body mass index; CAD ¼ coronary artery disease; HER2 ¼ human
epidermal growth factor receptor 2; HF ¼ heart failure; MI ¼ myocardial
infarction; VEGF ¼ vascular endothelial growth factor; VHD ¼ valvular heart
disease.
Table 4 Baseline risk factors for cardiotoxicity
Current myocardial disease Demographic and other 
CV risk factors
• Heart failure (with either preserved 
 or reduced ejection fraction)
• Asymptomatic LV dysfunction 
 (LVEF <50% or high natriuretic  
 peptidea)
• Evidence of CAD  (previous 
 myocardial infarction, angina, PCI or 
 CABG, myocardial ischaemia)
• Moderate and severe VHD with 
 LVH or LV impairment
• Hypertensive heart disease with 
 LV hypertrophy 
• Hypertrophic cardiomyopathy
• Dilated cardiomyopathy
• Restrictive cardiomyopathy
• Cardiac sarcoidosis with myocardial 
 involvement
• 
 (e.g. AF, ventricular tachyarrhythmias)
• Age (paediatric population 
 <18 years; >50 years for 
 trastuzumab; >65 years for 
 anthracyclines)   
• Family history of premature  
 CV disease (<50 years)
• Arterial hypertension
• Diabetes mellitus
• Hypercholesterolaemia
Previous cardiotoxic cancer 
treatment
Lifestyle risk factors
• Prior anthracycline use
• Prior radiotherapy to chest or 
 mediastinum
• Smoking
• High alcohol intake
• Obesity
• Sedentary habit 
Significant cardiac arrhythmias
AF ¼ atrial fibrillation; CABG ¼ coronary artery bypass graft; CAD ¼ coronary
artery disease; CV ¼ cardiovascular; LV ¼ left ventricular; LVEF ¼ left ventricular
ejection fraction; LVH ¼ left ventricular hypertrophy; VHD ¼ valvular heart
disease.
aB-type natriuretic peptide .100pg/ml or N-terminal pro-B-type natriuretic
peptide .400pg/ml with no alternative cause.
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assessment is often performed by the oncology team, but referral for
cardiology evaluation is highly recommended in high-risk patients.
High risk can be determined by both the number of risk factors
and their severity. Patients at high risk for developing cardiotoxicity
should be examined by a cardiologist with expertise in this field or,
if necessary, by a cardio-oncology specialist team.
Strategies for screening and detection of cardiotoxicity include
cardiac imaging [echocardiography, nuclear imaging, cardiac magnet-
ic resonance (CMR)] and biomarkers (troponin, natriuretic pep-
tides) (see Table 6). The choice of modalities depends upon local
expertise and availability, and several important core principles
should be considered:
† The same imaging modality and/or biomarker assay should be
used for continued screening throughout the treatment pathway.
Switching between modalities or assays is strongly discouraged.
† Modalities and tests with the best reproducibility are preferred.
† Imaging modalities that provide additional relevant clinical infor-
mation are preferred (e.g. right ventricular function, pulmonary
pressures, valvular function, pericardial evaluation).
† High quality radiation-free imaging is preferred, if available.
The precise timing and frequency of imaging and/or biomarker sam-
pling will depend upon the specific cancer treatment, total cumula-
tive dose of cardiotoxic chemotherapy, delivery protocol and
duration and the patient’s baseline cardiovascular risk.
2.1.2.2 Cardiovascular management of patients treated with
anthracyclines
For patients treated with adjuvant anthracyclines, baseline cardiac
function should be assessed. If systolic dysfunction or significant
VHD is found, the patient should be discussed with the oncology
team and options for non-anthracycline–containing chemotherapy
and/or cardioprotection should be considered. If used, a second as-
sessment of cardiac function should be performed at the end of the
treatment, particularly when the patient has an increased risk for
cardiotoxicity or consecutive treatment with potentially cardiotoxic
targeted therapies will follow. For higher-dose anthracycline-
containing regimens and in patients with high baseline risk, earlier
assessment of cardiac function after a cumulative total doxorubicin
(or equivalent) dose of 240 mg/m2 should be considered (see
Table 5).10,31,85 Measurement of at least one cardiac biomarker—
high-sensitivity troponin (I or T) or a natriuretic peptide—may be
considered at baseline, and determination of high-sensitivity troponin
I has been suggested with each cycle of anthracycline-containing
chemotherapy.86,87 To date, this suggested strategy has not been vali-
dated to prevent or improve longer-term toxicity events, but elevation
Table 5 Anthracycline equivalence dose considering
doxorubicin in rapid infusion as a reference94
Drug
Relative 
cardiotoxicity
Incidence of HF 
rises to >5% when 
cumulative dose 
exceeds (mg/m2)
Doxorubicin rapid 
infusion
1 400
Epirubicin 0.7 900
Daunorubicin ~0.75 800
Idarubicin 0.53 150
Table 6 Proposed diagnostic tools for the detection of cardiotoxicity
Technique
Currently available diagnostic 
criteria
Advantages Major limitations
Echocardiography:
 - 3D-based LVEF
 - 2D Simpson’s LVEF
 - GLS
• LVEF: >10 percentage points 
 decrease to a value below the LLN 
 suggests cardiotoxicity.
• GLS: >15% relative percentage 
 reduction from baseline may suggest 
 risk of cardiotoxicity.
• Wide availability.
• Lack of radiation.
• Assessment of haemodynamics and 
 other cardiac structures.
• Inter-observer variability.
• Image quality.
• GLS: inter-vendor variability, technical 
 requirements.
Nuclear cardiac imaging 
(MUGA)
• >10 percentage points decrease in 
 
 patients with cardiotoxicity.
• Reproducibility. • Cumulative radiation exposure.
• Limited structural and functional 
 information on other cardiac 
 structures. 
Cardiac magnetic resonance • Typically used if other techniques 
 
 presence of LV dysfunction if LVEF is 
 borderlines.
• Accuracy, reproducibility.
• Detection of diffuse myocardial 
 
 ECVF evaluation.
• Limited availability.
• Patient’s adaptation (claustrophobia, 
 breath hold, long acquisition times).
Cardiac biomarkers:
 - Troponin I
 - High-sensitivity Troponin I
 - BNP
 - NT-proBNP
• 
 
 
• Routine role of BNP and NT-proBNP 
 in surveillance of high-risk patient 
 needs futher investigation.
• Accuracy, reproducibility.
• Wide availability.
• High-sensitivity.
• 
 
• Variations with different assays.
• Role for routine surveillance not 
 clearly established.
LVEF with a value <50% identifies
are non-diagnostic or to confirm the
A rise identifies patients receiving
anthracyclines who may benefit from
ACE-Is.
fibrosis using T1/T2 mapping and
Insufficient evidence to establish the
significance of subtle rises.
ACE-Is ¼ angiotensin converting enzyme inhibitors; BNP ¼ B-type natriuretic peptide; ECVF ¼ extacellular volume fraction; GLS ¼ global longitudinal strain; LV ¼ left ventricular;
LLN ¼ lower limit of normality; LVEF ¼ left ventricular ejection fraction; MUGA ¼ multigated radionuclide angiography; NT-proBNP ¼ N-terminal fragment B-type natriuretic
peptide.
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of cardiac biomarkers identifies patients at greater risk for cardiotoxi-
city who may benefit from measures to prevent cardiotoxicity.
2.1.2.3 Cardiovascular management of patients treated with anti-HER2
Patients receiving anti-HER2 therapies frequently, though not
always, receive anthracyclines before starting the targeted therapy.
In such cases, surveillance should begin before anthracycline
administration. Standard screening during treatment depends on
local protocols and recommendations, but typically cardiac
monitoring is performed every 3 months during and once after com-
pletion of anti-HER2 treatment. Some investigators found that the
rate of clinically relevant trastuzumab-induced cardiac dysfunction
is substantially lower when a confirmatory LV assessment is carried
out 3 weeks after an initial (asymptomatic) LVEF decrease.52 Several
studies have demonstrated an improvement in early detection of
LVEF decrease when troponins and speckle tracking echocardiog-
raphy are used every 3 months during adjuvant trastuzumab treat-
ment. Given the variability in timing of trastuzumab-induced LV
dysfunction, measurement of troponin with every cycle may be con-
sidered in patients with high baseline risk.88–90
2.1.2.4 Cardiovascular management of patients treated with
VEGF inhibitors
The optimal timing of surveillance strategies for the various VEGF
inhibitors known to cause myocardial dysfunction still needs to be
clarified. After baseline assessment, some patients appear to de-
velop LV dysfunction early after treatment onset, whereas in others
this is delayed for several months. If baseline risk is high, it may be
appropriate to consider early clinical follow-up in the first 2–4
weeks after starting targeted molecular therapy with, for example,
sunitinib, sorafenib or pazopanib. Thereafter, the drug labels for
all of these drugs suggest a periodic reassessment of cardiac func-
tion, but do not state specifically when and how. Currently, it is rea-
sonable to consider periodic echocardiography, for example, every
6 months until stability in LVEF values is achieved. However, limited
evidence is available to support any specific surveillance strategy.
One observational study suggested surveillance every 2–3 months
with troponin or N-terminal pro-B-type natriuretic peptide
(NT-proBNP), and echocardiography detected myocardial toxicity
in 33% of patients taking VEGF inhibitors for renal cell carcinoma.9
2.1.2.5 Screening and early detection strategies
All patients receiving cardiotoxic chemotherapy should undergo a
cardiac assessment, including LV function, during follow-up after
treatment completion. A recent study reported a 9% incidence of
LV impairment following anthracycline chemotherapy in a large un-
selected cohort of 2625 patients, detectable in 98% of cases within
12 months following the last chemotherapy cycle.38 Long-term sur-
veillance should be considered for those who developed evidence
of cardiotoxicity during treatment and for those in whom cardio-
protective medication has been initiated, to determine whether a
trial of weaning is appropriate. Emerging data suggest that adults ex-
posed to high cumulative anthracycline doses and/or chest radio-
therapy should be offered lifelong surveillance, and this is now
recommended for survivors of childhood cancers.91,92 Additionally,
recommendations for monitoring survivors of adult-onset cancer
are currently under development.4,93
Baseline echocardiographic assessment of LV function is recom-
mended before initiation of potentially cardiotoxic cancer
treatment in all patients, irrespective of clinical history, in order to
confirm baseline risk. For low-risk patients (normal baseline
echocardiogram, no clinical risk factors), surveillance should be con-
sidered with echocardiography every 4 cycles of anti-HER2 treat-
ment or after 200 mg/m2 of doxorubicin (or equivalent) for
treatment with anthracyclines. More frequent surveillance may be
considered for patients with abnormal baseline echocardiography
(e.g. reduced or low normal LVEF, structural heart disease) and
those with higher baseline clinical risk (e.g. prior anthracyclines, pre-
vious MI, treated HF). Survivors who have completed higher-dose
anthracycline-containing chemotherapy (≥300 mg/m2 of doxorubi-
cin or equivalent) or who developed cardiotoxicity (e.g. LV impair-
ment) requiring treatment during chemotherapy may be considered
for follow-up surveillance echocardiography at 1 and 5 years after
completion of cancer treatment.
The optimal modality, extent and frequency of surveillance in
adults exposed to cardiotoxic cancer treatment who were asymp-
tomatic at the time of initial treatment remain unclear and are fre-
quently based on expert consensus rather than trial data.95
Retrospective observational data in elderly patients with breast
cancer treated with adjuvant anthracyclines show that the risk of
developing congestive HF continues to increase through .10 years
of follow-up.96 However, there was no such increase in risk of
congestive HF in the long-term follow-up of patients treated with ad-
juvant anthracyclines followed by trastuzumab.49,50 This finding is
most likely because the latter patients were substantially younger
and therefore their risk of developing cardiotoxicity was lower. Based
on these observations, it seems appropriate to conduct regular and
long-term surveillance in elderly patients and in patients with risk fac-
tors for cardiotoxicity who have been treated with anthracyclines.
2.1.2.6 Diagnostic tools to detect myocardial toxicity
Electrocardiography. ECG is recommended in all patients before
and during treatment. It is useful to detect any ECG signs of cardiac
toxicity, including resting tachycardia, ST-T wave changes, conduc-
tion disturbances, QT interval prolongation or arrhythmias. How-
ever, these ECG abnormalities are not specific and can be related
to other factors (see Table 10). Of note, these ECG changes can
be transitory and are not related to the development of chronic
cardiomyopathy.
Echocardiography. Echocardiography is the method of choice for
the detection of myocardial dysfunction before, during and
after cancer therapy (see Table 6).85,95 Unless three-dimensional
(3D) echocardiography is used, which is the best echocardiographic
method for measuring LVEF when endocardial definition is clear,
the two-dimensional (2D) biplane Simpson method is recommended
for estimation of LV volumes and ejection fraction in these patients.
Cancer therapeutics–related cardiac dysfunction (CTRCD) is defined
as a decrease in the LVEF of.10 percentage points, to a value below
the lower limit of normal.85,97 This decrease should be confirmed by
repeated cardiac imaging done 2–3 weeks after the baseline diag-
nostic study showing the initial decrease in LVEF. The LVEF decrease
may be further categorized as symptomatic or asymptomatic, or
with regard to reversibility.85 Although the exact interval is not es-
tablished, echocardiographic examination should be repeated dur-
ing follow-up to confirm recovery, or to detect irreversible LV
dysfunction. Echocardiography can also detect other complications
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of cancer therapy, including valvular and pericardial diseases and
findings suggestive of pulmonary hypertension.98,99
The main limitation of 2D echocardiography is its relatively
moderate reproducibility, which can be improved by the use of 3D
echocardiography. The latter is associated with the best day-to-day
reproducibility,100 but remains dependent on image quality, availabil-
ity and operator experience. For serial evaluation of patients with
cancer, LVEF measurements should ideally be performed by the
same observer with the same equipment to reduce variability.85
Other useful echocardiographic techniques include contrast
echocardiography, indicated in patients with suboptimal echocar-
diograms to improve delineation of the LV endocardial borders.
Stress echocardiography may be helpful in the evaluation of patients
with intermediate or high pretest probability for CAD, but no data
are available with regard to its prognostic value in patients with can-
cer for HF prediction. Doppler myocardial imaging and deformation
imaging is a promising tool and its use should be considered when-
ever possible. Several recent studies have shown the value of de-
formation imaging for early detection of LV dysfunction secondary
to cancer therapy.92 Global systolic longitudinal myocardial strain
(GLS) has been reported to accurately predict a subsequent de-
crease in LVEF.101,102 A relative percentage reduction of GLS of
.15% from baseline is considered abnormal and a marker of early
LV subclinical dysfunction. Until standardization of strain imaging
through different vendors is fully achieved, the current recommen-
dation is to use the same equipment for the longitudinal follow-up of
patients with cancer to facilitate the interpretation of results. These
advanced echocardiographic measurements are preferred, when
available, to serve as the basis for clinical decisions when performed
with adequate expertise at laboratories doing cardiac safety
studies.103
Diastolic dysfunction is common in patients with cancer, both at
baseline and during treatment; however, no evidence has shown
that treatment should be stopped based on these findings.
Nuclear cardiac imaging. Evaluation of LV function using multigated
radionuclide angiography has been used for years to diagnose
chemotherapy-induced cardiotoxicity with good accuracy and re-
producibility104 and few technical limitations. However, it is con-
strained by radiation exposure and provides only limited
additional information on cardiac structure and haemodynamics
(see Table 6). As echocardiography and multigated radionuclide
angiography have different reference values, the same technique
should be performed for baseline and follow-up studies.105,106
Cardiac magnetic resonance. CMR is a helpful tool for the evalu-
ation of cardiac structure and function. It is useful to determine
the cause of LV dysfunction and to clarify left and right ventricular
function in challenging cases (i.e. borderline or contradictory re-
sults from other imaging modalities).93,107 It also serves to evalu-
ate the pericardium, especially in patients with chest irradiation.
Late gadolinium imaging may be useful to detect scarring or
fibrosis, which may have prognostic implications in the context
of impaired LV function.108,109 Additionally, CMR is an excellent
test for the comprehensive evaluation of cardiac masses and infil-
trative conditions. Use of unique tissue characterization capabil-
ities of CMR (e.g. inflammation and oedema) will be dependent
on acceptance of T2 and T1 mapping and extracellular volume
fraction quantification (see Table 6). Diffuse anthracycline fibrosis
cannot be evaluated with conventional techniques of late gadolin-
ium enhancement.107
Cardiac biomarkers. The use of cardiac biomarkers during cardio-
toxic chemotherapy may be considered in order to detect early car-
diac injury (see Table 6). The challenge with the available published
data is the timing of the laboratory assessment relating to chemo-
therapy, the definition of the upper limit of normal for a specific
test, the use of different laboratory assays, as well as the challenge
of the strategy to undertake in case of an abnormal result.86,110
There is currently no clear evidence to withhold or interrupt
chemotherapy or targeted therapies based on a new abnormal car-
diac biomarker result, particularly with the application of increasing-
ly sensitive assays. However, an abnormal biomarker result is
indicative of an increased risk of cardiotoxicity.
Single-centre studies show, in patients receiving high-dose com-
bination chemotherapy, that a newly elevated cardiac troponin I
from a normal baseline may identify those who develop cardiac dys-
function with a poor prognosis, particularly when troponin eleva-
tion persists, and who may benefit from treatment with ACE
inhibitors.111–113 In patients treated with trastuzumab, particularly
when previously exposed to anthracyclines, troponin I elevation
can identify patients who will develop cardiac dysfunction and
who will not recover despite treatment for HF.88
New elevation of serum troponin I detected with high-sensitivity
troponin I assays in patients receiving anthracyclines and/or trastu-
zumab predicts subsequent LV dysfunction.89 In patients with breast
cancer, a small study demonstrated that the combination of high-
sensitivity troponin with GLS might provide the greatest sensitivity
(93%) and negative predictive value (91%) to predict future
cardiotoxicity.101
The role of cardiac biomarkers to detect cardiotoxicity due to
targeted molecular therapies including trastuzumab is still unclear.
Evidence supporting surveillance using troponin to predict future
LV dysfunction with the use of other immune and targeted cancer
therapies is still limited.
The use of natriuretic peptides to detect HF is widely established,
and even very low levels can identify high-risk patients and guide
therapy.113 In the context of chemotherapy, B-type natriuretic pep-
tide (BNP) and NT-proBNP may be useful, but their role in routine
surveillance to define the high-risk patient is not established.114
Future research needs to determine the optimal timing of
biomarker measurement for different chemotherapies and confirm
upper limits for each assay to better guide clinicians.
Surveillance and treatment strategies. The timing of cardiotoxicity
surveillance using echocardiography and biomarkers needs to be
personalized to the patient in the context of their baseline cardio-
vascular risk and the specific cancer treatment protocol pre-
scribed. The most important element is risk stratification to
guide the frequency of assessment and ensure that higher-risk pa-
tients have an earlier review to avoid missing early toxicity.115 This
is based on expert opinion, and evidence is lacking regarding the
optimal surveillance strategy to positively impact clinical out-
comes. Future research needs to establish the optimal timing of
biomarker measurement for the different cancer treatment path-
ways, confirm upper limits for each assay and better guide
clinicians to target cardioprotective therapy to the appropriate
patients with cancer.
Patients who develop asymptomatic LV dysfunction or HF during
cancer therapy are likely to profit from ACE inhibitors or angioten-
sin II receptor blockers (ARBs) and beta-blocker treatment similar
to the general HF population.116 More specifically, patients with
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anthracycline-induced cardiotoxicity have a better cardiac outcome
when treated with ACE inhibitors and/or beta-blockers early after
detection of cardiac dysfunction, and combination therapy may be
more effective than either treatment alone.36,38
2.1.3 Key points
† Cancer patients treated with potentially cardiotoxic therapy are at
high risk of developing HF and should therefore receive medical
care aimed at obtaining strict control of cardiovascular risk factors.
† LVEF should be determined before and periodically during treat-
ment for early detection of cardiac dysfunction in patients
receiving potentially cardiotoxic chemotherapy, with a method
that provides sufficient image quality and, preferably, using the
same method during follow-up.
† This group has decided to consider the lower limit of normal of LVEF
in echocardiography as 50%, in line with the definition of cardiotoxi-
city commonly used in registries and trials in patients with cancer.
† A patient with a significant decrease in LVEF (e.g. a decrease
.10%), to a value that does not drop below the lower limit of
normal, should undergo repeated assessment of LVEF shortly
after and during the duration of cancer treatment.
† If LVEF decreases.10% to a value below the lower limit of normal
(considered as an LVEF,50%), ACE inhibitors (or ARBs) in com-
bination with beta-blockers are recommended to prevent further
LV dysfunction or the development of symptomatic HF, unless
contraindicated, as these patients are at high risk of developing HF.
† ACE inhibitors (or ARBs) and beta-blockers are recommended in
patients with symptomatic HF or asymptomatic cardiac dysfunc-
tion unless contraindicated.
2.2 Coronary artery disease
2.2.1 Pathophysiology and clinical presentation
Myocardial ischaemia and, to a lesser degree, infarction and
ischaemia-induced arrhythmias are side effects of several cancer
therapies. The mechanisms by which these drugs cause myocardial
ischaemia are diverse and range from a direct vasospastic effect to
endothelial injury and acute arterial thrombosis, to long-term
changes in lipidmetabolism and consequent premature arteriosclerosis
(Table 7). Previous mediastinal radiotherapy may accelerate drug-
related coronary damage.
2.2.1.1 Fluoropyrimidines
Fluoropyrimidines such as 5-fluorouracil (5-FU) and its oral form
capecitabine are used to treat patients with gastrointestinal and
other malignancies. The incidence of myocardial ischaemia varies
considerably and may be as high as 10%, depending on dose, sched-
uling and route of administration.117 The mechanisms of 5-FU-
induced myocardial ischaemia are multifactorial and include coronary
vasospasm and endothelial injury.115 Chest pain and ischaemic ECG
changes typically occur at rest, and less frequently during exercise,
within days of drug administration and sometimes persist even after
treatment cessation. However, the problem of fluoropyrimidine-
induced myocardial ischaemia may be clinically underestimated; a re-
cent study found silent ischaemia in 6–7% of 5-FU-treated patients
examined using a stress test.124 5-FU can also result in acute myocar-
dial infarction.118
2.2.1.2 Cisplatin
Cisplatin may induce arterial thrombosis with subsequent myocar-
dial and cerebrovascular ischaemia in 2% of patients.119 The
pathophysiology is multifactorial, including procoagulant and direct
endothelial toxic effects. Cisplatin-treated survivors of testicular
cancer have a higher incidence of CAD, with an absolute risk of
up to 8% over 20 years.120,121
2.2.1.3 Immune and targeted therapeutics
Among the immune and targeted therapeutics, those inhibiting the
VEGF signalling pathway have an increased risk for coronary throm-
bosis. VEGF signalling is important for endothelial cell survival, and
inhibition can induce endothelial injury. The incidence of arterial
thrombosis varies depending on the compound and disease studied;
for the monoclonal VEGF antibody bevacizumab, it ranges from
,1% in the setting of adjuvant breast cancer to 3.8% in metastatic
diseases.60,122 A recent meta-analysis on the risk of arterial throm-
bosis induced by anti-VEGF small molecule TKIs found an overall
Table 7 Pathophysiological mechanisms of coronary artery disease in cancer treatment7,60,81,99,117 –123
Agent Pathophysiological mechanism Risk of coronary artery disease and acute 
coronary syndrome
Fluoropyrimidines
(5-FU, capecitabine, gemcitabine)
• Endothelial injury
• Vasospasm
• Up to 18% manifest myocardial ischaemia
• Up to 7–10%: silent myocardial ischaemia
Platinum compounds (cisplatin) • Procoagulant status
• Arterial thrombosis
• 20-year absolute risk of up to 8% after testicular cancer
• 2% risk of arterial thrombosis
VEGF inhibitors (bevacizumab, sorafenib, 
sunitinib)
• Procoagulant status
• Arterial thrombosis
• Endothelial injury
• Risk of arterial thrombosis: bevacizumab 3.8%, sorafenib 
 1.7%, sunitinib 1.4%
Radiotherapy • Endothelial injury
• Plaque rupture
• Thrombosis
• 2–7-fold increased relative risk of myocardial infarction
• Cumulative 30-year coronary events incidence of 10% in  
 Hogdkin lymphoma survivors
• Risk proportional to irradiation dose
5-FU ¼ 5-fluorouracil; VEGF ¼ vascular endothelial growth factor.
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incidence of 1.7% for sorafenib and 1.4% for sunitinib.123 Sorafenib
has also been reported to induce vasospasm.125
2.2.1.4 Radiotherapy
Supradiaphragmal and, in certain patient groups, even infradiaphrag-
mal radiotherapy may be associated with a higher incidence of is-
chaemic heart disease through the development of severe
atherosclerotic and non-atherosclerotic disease, complicated by
plaque rupture and thrombosis, and potentially with coronary
spasm.126 – 131 Ostial lesions are frequent and a potentially life-
threatening complication. The most exposed coronaries are the
left anterior descending during left breast irradiation and the left
main stem, circumflex and right coronary arteries during treatment
for Hodgkin lymphoma.132,133 A higher prevalence of stress test ab-
normalities has been found among women irradiated for left breast
cancer compared with right-sided cancer.134 The evolution may be
rapid, with acute coronary syndrome or sudden death as initial man-
ifestations, but it is more often asymptomatic for a long time.135,136
Radiation-related cardiac disease in patients with lymphoma typical-
ly manifests 15–20 years after the initial treatment, and younger pa-
tients are more susceptible than older patients.137 Survivors of
Hodgkin lymphoma have a four- to seven-fold increased risk of
CAD compared with the general population and a cumulative inci-
dence of CVD up to 50% 40 years after treatment.138 Based on
these data, it appears appropriate to screen regularly for cardiac dis-
eases patients who received radiation therapy, starting 10–15 years
after the initial cancer treatment and continuing lifelong. The risk of
developing CAD or CAD-associated events after chest irradiation is
modifiable by several factors, including concomitant chemotherapy
with anthracyclines, young age, high-fractionated doses, lack of thor-
acic shielding, cardiovascular risk factors and established CAD.95
The risk of myocardial infarction in patients treated for Hodgkin
lymphoma is two- to seven-fold higher than in the general popula-
tion, with a cumulative incidence of 10% at 30 years.7,81,99
2.2.2 Diagnostic and therapeutic management
The identification of patients with pre-existing CAD and other
CVDs is of paramount importance before initiating cancer treat-
ment. Data suggest that pre-existing CAD substantially increases
the risk of developing treatment-related CAD.95 In addition, pa-
tients who develop an acute coronary syndrome or symptomatic
CAD while thrombocytopenic during chemotherapy pose a par-
ticular challenge for treatment and need case-by-case multidisciplin-
ary management. Options for medical and interventional therapies
are limited, as the use of antiplatelet drugs and anticoagulants is fre-
quently not possible or must be restricted. In patients treated by
percutaneous coronary intervention who are subsequently found
to have a malignancy, minimal duration of dual antiplatelet therapy
should be pursued as far as reasonable, according to the most re-
cent guidelines,139–141 to limit bleeding risk. The diagnostic algo-
rithms used to identify CAD in patients with cancer are the same
as in patients without cancer, and echocardiography should be in-
cluded as part of the diagnostic workup in these patients.
The incidence and onset of CAD after radiation therapy is dose
dependent; historically, thoracic doses of .30 Gy were considered
to cause vascular disease.98,122,142 However, newer data indicate
that substantially lower radiation doses increase the risk of
subsequent CAD, and traditional risk factors for atherosclerosis
magnify the risk even more, expanding the population at risk.143
Typically there is a long latency period with asymptomatic CAD
after radiation treatment and patients may become symptomatic
10 years after the initial cancer therapy.143 Presentation of CAD
is more often atypical and the prevalence of silent ischaemia may be
higher than in conventional patients with CAD,144,145 possibly be-
cause of concomitant neurotoxicity of radiotherapy, or chemother-
apy affecting the patient’s perception of angina. Sudden cardiac
death in irradiated patients has been reported and linked to diffuse
intimal hyperplasia of all coronary arteries or to significant left main
stenosis.128,130,136 It is difficult to predict the burden of radiation-
induced CAD in the future, as the introduction of contemporary
heart-sparing radiation techniques should attenuate the problem.
These measures include a reduction in dose, tangential fields and
shielding of cardiac structures.
Long-term complications of treatment for testicular cancer in-
clude a greater than two-fold increased risk of CAD 10 years after
the initial treatment.120 These patients, who are typically in their 20s
or 30s when affected by the cancer, are commonly treated with a
multidrug cisplatin-based chemotherapy with or without radiation
therapy. After almost 20 years of follow-up, compared with patients
treated with surgery only, patients treated with chemotherapy and/
or (subdiaphragmal) radiation have more cardiovascular risk factors
and an 8% absolute risk for ischaemic events.137
2.2.3 Key points
† Assessment of CAD should be based on the history, age and gen-
der of the patient, considering the use of chemotherapy drugs as
a risk factor for CAD.
† Clinical evaluation and, when necessary, testing for detection of
myocardial ischemia is key to identify patients with latent pre-
existing CAD. This may have implications in the selection of can-
cer treatment.
† Patients treated with pyrimidine analogues should be closely
monitored for myocardial ischaemia using regular ECGs, and
chemotherapy should be withheld if myocardial ischaemia
occurs.
† Drug rechallenge after coronary vasospasm should be reserved
for when no other alternatives exist, and only under prophylaxis
and close monitoring of the patient. Pretreatment with nitrates
and/or calcium channel blockers may be considered in this
setting.
† Long-term clinical follow-up and, when required, testing for the
presence of CAD may be useful to identify patients with cardiac
disease who develop long-term complications of chemotherapy
and radiotherapy.
2.3 Valvular disease
2.3.1 Pathophysiology and clinical presentation
Chemotherapeutic agents do not directly affect cardiac valves, but
VHD may be observed in patients with cancer for several reasons,
including pre-existing valve lesions, radiotherapy, infective endocar-
ditis and secondary to LV dysfunction.85,98,128 Radiation-induced
VHD has been reported as common, affecting 10% of treated pa-
tients,99,146 and includes fibrosis and calcification of the aortic root,
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aortic valve cusps, mitral valve annulus and the base and mid por-
tions of the mitral valve leaflets, sparing the mitral valve tips and
commissures,98,99 allowing distinction from rheumatic disease.85 In
patients with Hodgkin lymphoma, radiation dose to the heart valves
can increase the risk of clinically significant VHD as the first cardio-
vascular event after treatment, especially at doses.30 Gy.147 How-
ever, for patients with mediastinal involvement treated today with
20 or 30 Gy, the 30-year risk would be increased only by 1.4%.146
2.3.2 Diagnostic and therapeutic management
Echocardiography is the assessment method of choice, and 3D
echocardiography may be useful, particularly for the evaluation of
mitral valve commissures. Baseline and repeated echocardiography
after radiation therapy involving the heart are recommended in pa-
tients with cancer for the diagnosis and follow-up of VHD.80,85,95,148
CMR and computed tomography (CT) may be used to assess the
severity of VHD, but cardiac CT is mainly useful for detecting exten-
sive calcifications of the ascending aorta, which may lead to a higher
operative risk and sometimes prohibit conventional cardiovascular
surgery. Cardiac surgery is also frequently challenging in such pa-
tients because of mediastinal fibrosis, impaired wound healing and
associated coronary artery, myocardial and pericardial disease.
Transcatheter valve implantation (e.g. transcatheter aortic valve im-
plantation) may be a suitable option in this situation.149
2.4 Arrhythmias
2.4.1 Pathophysiology and clinical presentation
Patients with cancer may experience a wide spectrum of cardiac ar-
rhythmias, including sinus tachycardia, bradyarrhythmias or tachyar-
rhythmias, and conduction defects, some of which may cause severe
symptoms or become life-threatening or impose a change in the pa-
tient’s treatment plan (Table 8). Arrhythmias can be present at base-
line in 16–36% of treated patients with cancer.11,150
2.4.1.1 QT prolongation
QT prolongation can be caused by cancer therapies (Table 9), elec-
trolyte disturbances, predisposing factors and concomitant medica-
tions (e.g. anti-emetics, cardiac medications, antibiotics,
psychotropes).11 QT prolongation can lead to life-threatening ar-
rhythmias such as torsade de pointes. The duration of the QT inter-
val and risk factors for QT prolongation should be controlled
before, during and after cancer treatment. The risk of QT prolonga-
tion varies with different drugs, with arsenic trioxide being the most
relevant. This drug, which is used to treat some leukaemias andmye-
lomas, prolongs the QT interval in 26–93% of patients, and life-
threatening ventricular tachyarrhythmias have been reported not in-
frequently.151 Prolongation of the QTc interval was observed 1–5
weeks after arsenic trioxide infusion and then returned towards
baseline by the end of 8 weeks, i.e. before the second course of
chemotherapy.152 Other cancer therapies that frequently induce
QT prolongation are listed in Table 9. Among these, the TKI drug
class, and specifically vandetanib, has the second highest incidence
of QT prolongation.
2.4.1.2 Supraventricular arrhythmia
Any type of supraventricular arrhythmia may arise acutely during or
even after chemotherapy or radiotherapy, of which atrial fibrillation
is the most common. The arrhythmia may be related to co-
morbidities or due to direct tumour effects, LV dysfunction or toxic
effects of the cancer treatment. The most common form of cancer-
related atrial fibrillation is postoperative atrial fibrillation, particular-
ly in patients undergoing lung resection. An overview of pathogen-
etic mechanisms has been published.151,155
2.4.1.3 Ventricular arrhythmias
Ventricular arrhythmias can be related to QT prolongation, to
acute and chronic toxicity of chemotherapy and radiotherapy
Table 8 Cancer drug agents associated with cardiac arrhythmias
Type of arrhythmia Causative drug
Bradycardia Arsenic trioxide, bortezomib, capecitabine, cisplatin, cyclophosphamide, doxorubicine, epirubicine, 5-FU, ifosfamide, 
IL-2, methotrexate, mitoxantrone, paclitaxel, rituximab, thalidomide.
Sinus tachycardia Anthracyclines, carmustine.
Atrioventricular block Anthracyclines, arsenic trioxide, bortezomib, cyclophosphamide, 5-FU, mitoxantrone, rituximab, taxanes, thalidomide.
Conduction disturbances Anthracyclines, cisplatin, 5-FU, imatinib, taxanes.
Alkylating agents (cisplatin, cyclophosphamide, ifosfamide, melphalan), anthracyclines, antimetabolites (capecitabine, 
5-FU, gemcitabine), IL-2, interferons, rituximab, romidepsin, small molecule TKIs (ponatinib, sorafenib, sunitinib, 
ibrutinib), topoisomerase II inhibitors (amsacrine, etoposide), taxanes, vinca alkaloids.
Supraventricular tachycardias Alkylating agents (cisplatin, cyclophosphamide, ifosfamide, melphalan), amsacrine, anthracyclines, antimetabolites 
(capecitabine, 5-FU, methotrexate), bortezomib, doxorubicin, IL-2, interferons, paclitaxel, ponatinib, romidepsin.
Alkylating agents (cisplatin, cyclophosphamide, ifosfamide), amsacrine, antimetabolites (capecitabine, 5-FU, 
gemcitabine), arsenic trioxide, doxorubicin, interferons, IL-2, methothrexate, paclitaxel, proteasome inhibitors 
Sudden cardiac death Anthracyclines (reported as very rare), arsenic trioxide (secondary to torsade de pointes), 5-FU (probably related 
to ischaemia and coronary spasm), interferons, nilotinib, romidepsin.
Atrial fibrillation
Ventricular tachycardia/fibrillation
(bortezomib, carfilzomib), rituximab, romidepsin.
5-FU ¼ 5-fluorouracil; IL-2 ¼ interleukin 2; TKI ¼ tyrosine kinase inhibitor.
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(mainly LV dysfunction and ischaemia) and to predisposing factors
(Table 10).
2.4.1.4 Sinus node dysfunction and conduction defects
Sinus node dysfunction and conduction defects may arise following
radiotherapy and are often permanent. Paclitaxel and thalidomide
can result in sinus node dysfunction and bradyarrhythmias and heart
block.151
2.4.2 Diagnostic and therapeutic management
Arrhythmias in patients with cancer can occur before, during and
shortly after treatment. Management should be individualized and
decisions on the use of anti-arrhythmic drugs or device therapy (im-
plantable or external wearable cardioverter defibrillators)156 should
consider the competing risks of cardiac- and cancer-related life ex-
pectancy, quality of life and complication risks.
2.4.2.1 QT interval and associated risk factors for QT prolongation
The QT interval and associated risk factors for QT prolongation
(Table 10) should be assessed before and during treatment. QTc in-
tervals .450 ms in men and .460 ms in women are suggested as a
guideline for the upper limit of normal on baseline ECG evalu-
ation.156,157 QTc prolongation .500 ms and a DQT (i.e. change
from baseline) of .60 ms are considered to be of particular con-
cern because torsades de pointes rarely occurs when QTc is
,500 ms.156 ECG and electrolyte monitoring during treatment
Table 9 Cancer drug agents associated with QT prolongation and Torsade de Pointes151,153,154
Cancer drug agents
Average QT 
prolongation (ms)
Increase in 
QTc >60 ms (%)
QTc >500 ms (%)
Torsade de pointes 
(%)
Anthracyclines
Doxorubicin 14 11–14 NA NA
Histone deacetylase inhibitors
Depsipeptide 14 20–23.8 NA NA
Vorinostat <10 2.7–6 <1 NA
Tyrosine kinase inhibitors
Axitinib <10 NA NA NA
Bosutinib NA 0.34 0.2 NA
Cabozantinib 10–15 NA NA NA
Crizotinib 9–13 3.5 1.3 NA
Dasatinib 3–13 0.6–3 <1.4 NA
Lapatinib 6–13 11 6.1 NA
Nilotinib 5–15 1.9–4.7 <1.2 NA
Pazopanib NA NA 2 <0.3
Ponatinib <10 NA NA NA
Sorafenib 8–13 NA NA NA
Sunitinib 9.6–15.4 1–4 0.5 <0.1
 Vandetanib 36 12–15 4.3–8 Described, % NA
Vemurafenib 13–15 1.6 1.6 Described, % NA
Others
Arsenic trioxide 35.4 35 25–60 2.5
NA ¼ not available.
Table 10 Risk factors for QT prolongation in cancer
patients
Risk factors for QT prolongation
Correctable Non-correctable
Electrolyte imbalance
 • Nausea and emesis
   • Diarrhoea
   • Treatment with loop diuretics
   • Hypokalaemia (≤3.5 mEq/L)
   • Hypomagnesaemia (≤1.6 mg/dL)
   • Hypocalcaemia (≤8.5 mg/dL)
Hypothyroidism
Concurrent use of 
QT-prolonging drugs
  • Antiarrhythmic
  • Anti-infective
  • Antibiotic
  • Antifungal
  • Psychotropic
  • Antidepressant
  • Antipsychotic
  • Antiemetic
  • Antihistamine
• Family history of sudden 
 death (occult congenital 
 LQTS or genetic
 polymorphisms)
• Personal history of syncope
• Baseline QTc interval 
 prolongation
• Female gender
• Advanced age 
• Heart disease
• Myocardial infarction
• Impaired renal function
• Impaired hepatic drug 
 metabolism
LQTS ¼ long QT syndrome.
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should be considered at baseline, 7–15 days after initiation or
changes in dose, monthly during the first 3 months and then period-
ically during treatment depending on the chemotherapy drug and
patient status. Patients experiencing diarrhoea should
be monitored more frequently, and those receiving treatment
with arsenic trioxide should be monitored weekly with ECG.
Management is generally dependent on correcting the pre-
disposing factors (e.g. concomitant electrolyte abnormalities,
QT-prolonging drugs). A full list of QT-prolonging drugs and which
concomitant drugs should be avoided whenever possible can be
found at http://www.crediblemeds.org. A general recommendation
from the US Food and Drug Administration and European Medi-
cines Agency is that if during treatment QTc is .500 ms (or QTc
prolongation is .60 ms above baseline), treatment should be tem-
porarily interrupted, electrolyte abnormalities corrected and car-
diac risk factors for QT prolongation controlled.151,154,156
Treatment can then be resumed at a reduced dose once the QTc
normalizes. As malignancy is usually associated with substantial
morbidity and mortality, benefits from the efficacy of targeted
therapies have the potential to outweigh the risk of torsade de
pointes.154,155,158 If no alternative therapy exists, the frequency of
ECG monitoring of the QT interval should be increased. The fre-
quency of monitoring should be individualized depending on the
patient’s characteristics and the causative drug.
The development of bursts of torsade de pointes is unusual, but
requires intravenous administration of magnesium sulphate (10 mL)
and, in some acute situations, overdrive transvenous pacing or iso-
prenaline titrated to a heart rate .90 beats per minute to prevent
new episodes in the acute setting. If sustained ventricular arrhyth-
mias and haemodynamic instability occur, non-synchronized defib-
rillation must be performed.
2.4.3 Key points
† A 12-lead ECG should be recorded and the QT interval, cor-
rected for heart rate with Bazett’s or Fridericia’s formula, should
be obtained in all patients at baseline.
† Patients with a history of QT prolongation, relevant cardiac dis-
ease, treated with QT-prolonging drugs, bradycardia, thyroid
dysfunction or electrolyte abnormalities should be monitored
by repeated 12-lead ECG.
† Consider treatment discontinuation or alternative regimens if the
QTc is .500 ms, QTc prolongation is .60 ms or dysrhythmias
are encountered.
† Conditions known to provoke torsades de pointes, especially
hypokalaemia and extreme bradycardia, should be avoided in
patients with drug-induced QT prolongation.
† Exposure to other QT-prolonging drugs should be minimized in
patients treated with potentially QT-prolonging chemotherapy.
2.4.3.1 Atrial fibrillation and atrial flutter
The initial approach to themanagement of atrial fibrillation and atrial
flutter requires the usual decisions regarding rhythm management,
thromboembolic prophylaxis and effective stroke prevention with
oral anticoagulation. However, the balance between thrombo-
embolic and bleeding risks of atrial fibrillation {as assessed by the
CHA2DS2-VASc [Congestive heart failure or left ventricular
dysfunction, Hypertension, Age ≥75 years (doubled), Diabetes,
Stroke (doubled), Vascular disease, Age 65–74 years, Sex category
(female)] and HAS-BLED [Hypertension, Abnormal renal/liver func-
tion (1 point each), Stroke, Bleeding history or predisposition, Labile
international normalized ratio, Elderly (.65 years), Drugs/alcohol
concomitantly (1 point each)] scores, respectively} is particularly
challenging in patients with cancer. While cancer may cause a pro-
thrombotic state, it may also predispose to bleeding. On the other
hand, the CHA2DS2-VASc andHAS-BLED risk scores have not been
validated in patients with cancer. Thus the decision on antithrombo-
tic therapy for stroke prevention may be quite challenging and
should not be based only on the risk assessment scores used for
the general population.
In patients with a CHA2DS2-VASc score ≥2, anticoagulation can
generally be considered if the platelet count is .50 000/mm3, usu-
ally with a vitamin K antagonist and with good anticoagulation con-
trol (with time in the therapeutic range .70%). Close liaison with
haematologists/oncologists is advised. The occurrence of atrial fib-
rillation at any point (e.g. during chemotherapy, surgery or radio-
therapy) suggests an intrinsic predisposition to arrhythmia. In
terms of thromboprophylaxis, this again depends on the presence
of stroke risk factors, where anticoagulation would be recom-
mended with a CHA2DS2-VASc score ≥2. Even with lower-risk pa-
tients with atrial fibrillation, prophylaxis may be considered, given
the risk of venous thromboembolism (VTE) in patients with cancer.
Full assessment of the patient, including echocardiography, is
advised, and decisions on anticoagulation should consider other
co-morbidities, bleeding risks and patient values and preferences.
Anticoagulation options include therapeutic low molecular weight
heparin (LMWH) (as a short- to intermediate-term measure), a vita-
min K antagonist (VKA; e.g. warfarin) if the international normalized
ratio control is stable and effective or a non-VKA oral anticoagulant
(NOAC).Warfarin is often avoided in cancer patients with metastatic
disease and high bleeding risk, with LMWH the traditionally preferred
option, given the risk for variations in the international normalized ratio.
The role and safety of NOACs in this patient group remains to be clari-
fied. Although trials generally excluded patients with a platelet count of
,100 000/mm3 or limited survival, a meta-analysis of the patients with
cancer in NOAC trials suggested these new drugs are safe.159
Generally, an individualized approach to the management of atrial
fibrillation is needed, and decisions on rate or rhythm control should
be patient-centred and symptom directed. A beta-blocker or non-
dihydropyridine calcium channel blocker may help with rate control
in atrial fibrillation and with suppression of supraventricular tachycar-
dia. Digitalis may be considered as an alternative in patients with
intolerance to the former, with systolic dysfunction or HF.
2.4.3.2 Bradycardia or atrioventricular block
The development of bradycardia or atrioventricular block requires
an individualized approach to management, with correction of the
causative factor(s), when feasible, before decisions are made on
drugs and/or pacing (whether temporary or permanent).
2.5 Arterial hypertension
2.5.1 Pathophysiology and clinical presentation
Hypertension is a frequent co-morbidity in patients with cancer. It
can also be a causative factor, such as in renal cancer.160 VEGF
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inhibitors have a high risk (11–45%) of inducing new hypertension
or destabilizing previously controlled hypertension, including severe
hypertension in 2–20% of cases.161,162 The incidence and severity
depend upon patient age, history of hypertension, CVD history,
type of cancer (i.e. renal vs. non-renal cell cancer), drug type and
dose, schedule used and associated cancer therapies. In a
meta-analysis of clinical trials, the incidence of hypertension was in-
creased by a factor of 7.5, 6.1 and 3.9, respectively, under bevacizu-
mab, sorafenib and sunitinib.163,164
A summary of the incidence of hypertension reported in patients
with cancer taking these drugs can be found in the appendix at the
end of this document. Nitric oxide pathway inhibition, vascular rar-
efaction (i.e. reduced number of vessels), oxidative stress and glom-
erular injury developing from loss of VEGF effect represent some of
the main proposed mechanisms.162,163 VEGF inhibition may also
cause renal thrombotic microangiopathy.164 Drug-related hyper-
tension can occur from initiation until 1 year after treatment onset.
In the case of sunitinib, cancer efficacy may be correlated with the
occurrence and degree of hypertension, but there is no evidence
that antihypertensive therapy impairs oncology responses.9
2.5.2 Diagnostic and therapeutic management
Management of hypertension aims at reducing the short-term risk of
its related morbidities while maintaining effective anti-angiogenic
therapy for optimal cancer treatment.165 The goal is to identify
hypertension (.140/90 mmHg) and maintain blood pressure
(,140/90 mmHg, or lower in case of overt proteinuria). Baseline
assessment of CVD risk factors (including a history of hypertension
and current blood pressure levels) and management of arterial
hypertension should be performed before initiation of a VEGF in-
hibitor. Pain control and stress management are necessary for ad-
equate estimation of blood pressure. Other medications used in
these patients (e.g. steroids, non-steroidal anti-inflammatory drugs,
erythropoietin) may also predispose to or cause hypertension.
When white-coat hypertension is suspected, ambulatory blood
pressure measurement should be considered and lifestyle modifica-
tion encouraged.166
After the initiation of VEGF inhibitors, early detection and
reactive management of blood pressure elevations are necessary
to avoid severe complications, and aggressive pharmacological
management is recommended.167 – 171 ACE inhibitors, ARBs and
non-dihydropyridine calcium channel blockers (amlodipine, felodi-
pine) are proposed as first-line therapies.172 ACE inhibitors and
beta-blockers are the preferred antihypertensive drugs in patients
with HF or at risk of HF or LV dysfunction.173 Because decreased
nitric oxide signalling plays a key role in the pathogenesis of hyper-
tension,169 drugs that increase nitric oxide signalling, such as the
beta1-blocker nebivolol, may represent a valuable option in this
population.116 Other beta-blockers with vasodilatory effects, such
as carvedilol, can be considered. Diltiazem and verapamil inhibit
cytochrome P450 3A4, and because many VEGF inhibitors are a
substrate of this isoenzyme, this combination results in increased
drug plasma levels and should therefore be avoided. Inhibitors of
phosphodiesterase-5, such as sildenafil and tadalafil, may also offer
an antihypertensive therapy option, although available data are lim-
ited in patients with arterial hypertension.174,175 Diuretics have the
risk of electrolyte depletion and consequent QT prolongation and,
although theymay be used, caution is advised and they should not be
considered as first-line therapy because VEGF inhibitors can pro-
duce severe diarrhoea and potential dehydration.9,172 However,
there is minimal trial-based evidence suggesting a superiority of
any specific class of antihypertensive drug in patients treated with
these VEGF inhibitors.175,176
Close monitoring and evaluation of treatment adherence are
necessary when severe hypertension is present. To ensure efficacy
and tolerance of antihypertensive drugs, follow-up is mandatory.
Patients with resistant hypertension should be referred to cardio-
oncology or hypertension specialist assessment to minimize inter-
ruption of VEGF inhibitors.
2.5.3 Key points
† Hypertension should be adequately treated according to the cur-
rent standing clinical practice guidelines, and blood pressure
should be monitored before initiating cancer treatment and peri-
odically during treatment, depending on the patient’s character-
istics and adequate blood pressure control.
† Hypertension in patients with cancer is manageable with con-
ventional antihypertensive treatment, but early and aggressive
treatment is encouraged to prevent the development of cardio-
vascular complications (i.e. HF).
† ACE inhibitors or ARBs, beta-blockers and dihydropyridine cal-
cium channel blockers are the preferred antihypertensive drugs.
Non-dihydropyridine calcium channel blockers should preferably
be avoided due to drug interactions.
† Dose reduction and reinforcement of antihypertensive treatment
or discontinuation of VEGF inhibitors can be considered if blood
pressure is not controlled. Once blood pressure control is
achieved, VEGF inhibitors can be restarted to achieve maximum
cancer efficacy.
2.6 Thromboembolic disease
2.6.1 Pathophysiology and clinical presentation
Tumour cells can trigger coagulation through different pathways, in-
cluding procoagulant, antifibrinolytic and pro-aggregating activities;
release of pro-inflammatory and pro-angiogenic cytokines and inter-
action with vascular and blood cells through adhesion molecules.177
2.6.1.1 Arterial thrombosis
Intra-arterial thrombotic events are rare in patients with cancer,
with an incidence of 1%. They occur mostly in metastatic pancre-
atic, breast, colorectal and lung cancers, under anthracyclines and
taxane- and platinum-based chemotherapies, and affected patients
have a poor prognosis.178 The prothrombotic state may facilitate
embolic events secondary to atrial fibrillation (see section 2.4.3.1).
Some cancer therapies, especially VEGF inhibitors, may favour
thromboembolic complications9 (see section 2.2). In patients with
breast cancer under hormonal therapy, higher rates of arterial
thrombotic events are reported under aromatase inhibitors com-
pared with tamoxifen, which are at least partly explained by the
more favourable effects of tamoxifen on the lipid profile.179
2.6.1.2 Venous thrombosis and thromboembolism
Venous thrombosis and VTE occur frequently in patients with can-
cer, may affect up to 20% of hospitalized patients and are frequently
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underrecognized.180 They can be related to chemotherapy, includ-
ing its administration route (use of indwelling venous catheters), and
also to the cancer itself and the patient’s previous risk of venous
thrombosis. VTE is the most common cause of death after surgery
for cancer. Antithrombotic prophylaxis should be given for a min-
imum of 4 weeks after surgery. VTE is common in ambulatory pa-
tients with cancer (bladder, colon, ovary, lung, stomach and
pancreas) during chemotherapy treatment; however, the role of
prophylaxis is unclear. Improved patient selection and/or antithrom-
botic agents are required.181 Table 11 summarizes clinical risk fac-
tors associated with VTE.182 Some biological factors are also
considered as predictive of VTE in cancer (platelet count, leucocyte
count, d-dimers, etc.). The combination of chemotherapy and VEGF
inhibitors increases the risk of VTE and recurrent VTE six-fold and
two-fold, respectively.183 In patients with breast cancer, higher rates
of VTE are reported under tamoxifen compared with aromatase
inhibitors.181
2.6.2. Diagnostic and therapeutic management
The detection of thrombotic events in patients undergoing chemo-
therapy is based mainly on clinical symptoms. No systematic screen-
ing strategy has shown any benefit. Incidental pulmonary embolism
or venous thrombosis can be detected during imaging for cancer
(e.g. chest positron emission tomography–computed tomography).
The management of these silent thrombotic events is still unclear.
As the risk for (symptomatic) recurrence and mortality is increased,
these cases are usually treated in a similar manner to symptomatic
VTE.184
The decision to administer anticoagulation for VTE prevention
in patients with cancer should always take into consideration the pa-
tient’s bleeding risk and life expectancy; these may change over time,
requiring periodic reassessment. Treatment of a confirmed episode
of acute VTE in haemodynamically stable patients consists of
LMWH given over a period of 3–6 months. This strategy is superior
to VKA therapy in patients with cancer in terms of reduced VTE
events, with no difference regarding mortality or bleeding in clinical
trials.185 Bleeding risk can be six times higher under anticoagulation
for deep vein thrombosis in patients with vs. without cancer.186
Cancer is a strong risk factor for VTE recurrence. Consequently,
chronic anticoagulation after the acute phase of treatment, and until
the cancer is considered cured, should be considered. The choice of
anticoagulation discontinuation or maintenance under LMWH or
switching to VKAs should be discussed on an individual basis after
considering the cancer therapy success, the risk of VTE recurrence
and bleeding, as well as the patient’s preference.187 Current data on
NOACs are limited to a subgroup analysis of patients with cancer
within large trials comparing these drugs with VKAs in VTE.188,189
Overall, no differences were reported between NOACs and
VKAs for either VTE recurrence or bleeding. Results from specific
trials involving NOACs in patients with cancer are awaited. No
comparison between NOACs and LMWH is currently available.
Different NOACs may differ because of potential drug
interactions and sensitivity to renal or hepatic dysfunction.190
Recurrent VTE may still occur despite VKA or LMWH therapy in
patients with cancer, and may bemanaged by switching from VKA to
LMWH or increasing the LMWH dose.191 A vena cava filter, either
definitive or retractable, may be implanted when anticoagulation is
contraindicated or failing. However, the risk of filter thrombosis and
occlusion leading to distal propagation of thrombosis with post-
thrombotic syndrome should be considered. No clinical advantage
was found in the systematic placement of a vena cava filter in add-
ition to anticoagulation with fondaparinux in patients with
cancer.192
There is no conclusive evidence on the benefits of thrombolysis
in case of haemodynamically unstable pulmonary embolism in pa-
tients with cancer. Increased bleeding risk should be expected,
but because of high pulmonary embolism–related early mortality
risk, thrombolysis may still be considered, on a case-by-case basis,
taking into account the patient’s quality-adjusted life expectancy re-
lated to the individual cancer. It is important to keep in mind contra-
indications to fibrinolytic therapy in patients with brain tumours or
metastasis. Surgical embolectomy may be considered, but surgery
imparts significant morbidity, and cardiopulmonary bypass requires
aggressive anticoagulation.189
The management of arterial thrombotic events in patients with
cancer has been poorly addressed, and the use of antithrombotic
therapies, thrombolysis and/or endovascular intervention should
be discussed on a case-by-case basis with multidisciplinary consult-
ation involving the cardio-oncology team, when available. In case of
recurrences, control of cardiovascular risk factors and the search
for anti-phospholipid antibodies has been proposed.193
2.7. Peripheral vascular disease and
stroke
2.7.1 Pathophysiology and clinical presentation
2.7.1.1 Peripheral artery disease
Severe atherosclerotic and non-atherosclerotic peripheral artery
disease (PAD) in the lower extremities can occur (in up to 30%)
in patients treated with nilotinib, ponatinib or BCR-ABL TKIs used
for chronic myeloid leukaemia, even in the absence of CVD risk
Table 11 Clinical factors associated with increased
risk of cancer-associated venous thromboembolism
(modified from Khorana et al.182)
Cancer-related factors
• Primary site of cancer (mostly pancreas, brain, stomach, kidney, lung, 
 lymphoma, myeloma)
• Histology (specially adenocarcinoma)
• Advanced stage (metastatic)
• Initial period after cancer diagnosis
Patient-related factors
• Demographics: older age, female sex,  African ethnicity
• Comorbidities (infection, chronic kidney disease, pulmonary disease,  
 atherothrombotic disease, obesity)
• History of venous thromboembolism, inherited thrombophilia
• Low performance status
Treatment-related factors
• Major surgery
• Hospitalization
• Chemotherapy and anti-angiogenic agents
• Hormonal therapy
• Transfusions
• Central venous catheters
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factors, although the latter increases the likelihood of PAD.74 PAD
can occur as early as in the first months of therapy or as a late effect
several years after treatment. Other cancer therapy–related per-
ipheral arterial toxicity includes Raynaud’s phenomenon and ischae-
mic stroke (i.e. with L-asparaginase, cisplatin, methotrexate, 5-FU
and paclitaxel).194
2.7.1.2 Stroke
The risk of stroke is increased—at least doubled—after mediastinal,
cervical or cranial radiotherapy.195 Endothelial damage and throm-
bus formation may occur after irradiation of cerebral small
vessels.196 In medium or large vessels, three mechanisms are de-
scribed: vasa vasorum occlusions with medial necrosis and fibrosis;
adventitial fibrosis and accelerated atherosclerosis, leading to in-
creased carotid stiffness and intima-media thickness and advanced
atherosclerosis (occurring .10 years after radiotherapy).197,198
Similar consequences are reported for the aorta and other periph-
eral arteries, including the subclavian and iliofemoral, with ischaemic
limb symptoms.199
2.7.2 Diagnostic and therapeutic management
The assessment of PAD risk at baseline (risk factor assessment,
clinical examination, ankle–brachial index measurement) is recom-
mended. Fontaine stages 1–2 (asymptomatic or with intermittent
claudication only) require risk factor control and periodic clinical,
metabolic and haemodynamic follow-up.200 Antiplatelet drugs
should be considered mostly in symptomatic PAD. In case of
severe PAD at baseline or during cancer therapy, revascularization
should be individualized and discussed in a multidisciplinary meeting
with experts in haematology, vascular surgery and
cardio-oncology.201
Patients irradiated for head and neck cancer or lymphoma should
undergo cerebrovascular ultrasound screening, especially beyond
5 years after irradiation. Duplex imaging may be considered at least
every 5 years, or earlier and/or more frequently if the results of the
first examination are abnormal. Other locations of post-radiation
arterial lesions are usually discovered by clinical examination or
when symptomatic. Stringent risk factor management is required
to halt plaque progression. Antiplatelet therapy may be considered.
Significant stenosis (e.g. carotid arteries) may require stenting or
surgery.201,202
2.8 Pulmonary hypertension
2.8.1 Pathophysiology and clinical presentation
Pulmonary hypertension is a rare but serious complication of some
cancer agents and stem cell bone marrow transplantation.203 The
TKI imatinib improved haemodynamics in patients with advanced
pulmonary arterial hypertension (PAH).204,205 However, a drug of
the same TKI family—dasatinib, used as second-line treatment for
chronic myelogenous leukaemia—can induce severe precapillary
pulmonary hypertension.206 This condition appears 8–40 months
after exposure to dasatinib, with clinical and haemodynamic presen-
tation suggestive of PAH. Unlike other forms of PAH, this is often
reversible after drug discontinuation or replacement with another
TKI, such as nilotinib. Recently, cyclophosphamide and other alkyl-
ating agents were suggested as contributing to the development of
pulmonary veno-occlusive disease,207 involving predominantly small
venules and representing the most severe form of pulmonary hyper-
tension lacking effective pharmacological treatment.
2.8.2 Diagnostic and therapeutic management
Baseline echocardiographic assessment, including the search for
signs of right ventricular overload, should be considered in indivi-
duals requiring treatment with cancer drugs that can cause pulmon-
ary hypertension (e.g. dasatinib) (Table 12). This approach may help
in interpretation of follow-up echocardiographic examinations in
patients reporting exercise limitation or exertional dyspnoea during
cancer therapy. Patients with echocardiographic signs suggesting in-
creased baseline pulmonary arterial pressure require cardiology as-
sessment to determine its aetiology, as it may affect the strategy of
cancer treatment, particularly when due to LV dysfunction or
chronic thromboembolic pulmonary hypertension.208
Non-invasive cardiovascular surveillance should be considered
in all patients during treatment with cancer drugs known to cause
PAH, particularly in case of the appearance of new exertional
dyspnoea, fatigue or angina (Table 12). Echocardiography may be
considered every 3–6 months in asymptomatic patients. It is
unclear whether patients with baseline signs of right ventricular
overload due to co-morbidities commonly associated with
elevated pulmonary arterial pressure (e.g. chronic obstructive
pulmonary disease, left heart dysfunction) are at higher risk of
chemotherapy-induced PAH and require more frequent surveil-
lance with echocardiography.
Table 12 Strategies for surveillance and management
of drug-induced pulmonary hypertension
Baseline 
assessment
• Consider risk factors and associated conditions for 
 PAHa
• Assess NYHA/WHO functional class
• Consider 6-minute walk test
• Consider NT-proBNP
• Assess echocardiographic level of probability of PH
Surveillance 
strategy
Asymptomatic
• Assess NYHA/WHO functional class every 3 months
• Assess echocardiographic level of PAP every 
 3 months
• Consider presence of other indications for right heart 
 catheterization
• Consider further evaluation for suspected PHa
Symptomatic   
• Assess NYHA/WHO functional class
• Perform 6-minute walk test
• Sample blood for NT-proBNP
• Assess echocardiographic level of probability of PH
• Consider indications for right heart catheterization
 in PH referral centrea
• Consider interruption of cancer therapyb
NT-proBNP¼ N-terminal fragment B-type natriuretic peptide; NYHA¼ New York
Heart Association; PAH ¼ pulmonary arterial hypertension; PAP ¼ pulmonary
arterial pressure; PH¼ pulmonary hypertension; WHO ¼World Health
Organization.
aSee diagnostic algorithms for suspected PH in European Society of Cardiology (ESC)/
European Respiratory Society (ERS) Guidelines on Pulmonary Hypertension
(2015)208.
bDasatinib-induced PH usually reversible with drug cessation.
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When drug-induced PAH is suspected, referral to a specialized
pulmonary hypertension team is recommended to assess indica-
tions for right heart catheterization.208 Multidisciplinary team dis-
cussions should be held with oncology or haematology regarding
the risk–benefit ratio of continuing cancer treatment with PAH
drug therapy vs. stopping or replacing the culprit drug.208
Dasatinib-induced pulmonary hypertension is often reversible
with drug cessation, although usually without restoration of normal
right heart haemodynamics.206 Targeted therapy for PAH is used
temporarily or permanently.
2.9 Other cardiovascular complications of
cancer treatment
2.9.1 Pericardial disease
Acute pericarditis may occur with the use of several chemothera-
peutic drugs (predominantly anthracyclines, but also cyclophospha-
mide, cytarabine and bleomycin), while it has become uncommon
during radiotherapy and is usually associated with pericardiac medi-
astinal tumours. Acute pericarditis with typical chest pain, fever,
ST-T changes and large effusions, even leading to tamponade, may
develop 2–145 months after thoracic radiotherapy, with an abso-
lute cumulative incidence of 2–5%. Transthoracic echocardiography
is the method of choice for the evaluation of patients with suspected
pericardial disease due to chemotherapy, but CT can be of help, par-
ticularly to identify calcification. Treatment of pericardial effusion
consists primarily of non-steroidal anti-inflammatory drugs and col-
chicine. Pericardiocentesis may be required for large effusions and
those causing haemodynamic compromise, eventually followed by
surgical pericardial windowing.
Delayed pericardial disease may develop 6 months to 15 years
after radiation treatment95,209,210 and includes pericarditis and
chronic pericardial effusion (usually asymptomatic). Although
most cases resolve spontaneously, there are reports of occurrence
of chronic and/or constrictive pericarditis after high-dose radiother-
apy administration in up to 20% of patients.211,212
2.9.2 Pleural effusion
Pleural effusion related to the cancer itself, HF, infections or other
causes is common in patients with cancer. Some cancer drugs (e.g.
dasatinib and imatinib) may induce fluid retention or a reversible
pleural effusion through additional unknown mechanisms.213
2.9.3 Autonomic dysfunction
Radiotherapy damage to the cardiac nervous system may lead to
sympathetic–vagal imbalance characterized by inappropriate sinus
tachycardia, altered heart rate variability and decreased sensitivity.
This may lead to a higher pain threshold or silent ischaemia in cancer
survivors with manifest CAD.214 Its management does not differ
from that in non-cancer patients.
2.10 Cardiovascular complications of
cancer treatment in special populations
Cardiotoxicity of cancer therapy has special characteristics in some
clinical subgroups.
2.10.1 Paediatric cancer population
A steadily growing number of childhood cancer survivors have to
face lifelong side effects of cancer therapies, some of them affecting
the cardiovascular system.91–93 Indeed, the risk for severe cardio-
vascular conditions is increased eight-fold, putting cardiac disease
among the leading causes of death in long-term survivors of child-
hood cancer.215 Anthracyclines and radiotherapy are the most com-
monly implicated cardiotoxic agents in childhood cancer.216 A
recent large follow-up trial found cardiovascular complications in
8.1% of .32 000 childhood cancer survivors. Therapies for hepatic
cancer, Hodgkin lymphoma and leukaemia were related to the high-
est overall risks for CVD, with HF {relative risk 5.2 [95% confidence
interval (CI) 4.5–5.9]} the most common, followed by valvular dys-
function [relative risk 4.6 (95%CI 3.8–5.5)] and cerebrovascular dis-
eases [relative risk 3.7 (95% CI 3.4–4.1)]. Compared with a control
group, the risk for any CVD varied considerably, with an almost
20-fold increase in young patients comparedwith merely 1.3 for sur-
vivors .60 years of age due to a sharp increase in the incidence of
common CVD.217 A recently published harmonization of inter-
national guidelines recommends lifelong follow-up for survivors of
childhood cancer treated with either high-dose anthracyclines, high-
dose radiotherapy to the chest or both.91,92
2.10.2 Elderly patients
Elderly patients treated with cancer therapy are the second subpo-
pulation most commonly affected by cardiotoxicity, due largely to
the common prevalence of classic cardiovascular risk factors and
co-morbidities. A history of HF, cardiac dysfunction, arterial hyper-
tension, diabetes or CAD all make the cardiovascular system more
vulnerable to the additional burden of chemotherapy or radi-
ation.218–220
2.10.3 Pregnant women
There is very little evidence regarding maternal risk of cardiotoxi-
city. It can be expected that cardiotoxicity can be influenced by
pharmacokinetic and pharmacodynamic changes occurring during
pregnancy. In a recent review, the authors mentioned decreased an-
thracycline plasma levels in pregnant vs. non-pregnant women.221
On the other hand, cardiovascular overload due to the high-output
state in pregnancy may counterbalance this toxicity-limiting effect
and the net result is difficult to predict. Data from a small registry
and a case–control trial involving 10 pregnant women suggest
that the cardiotoxicity risk in pregnancy is similar to that of an age-
matched female population.222,223 However, in view of uncertainties
and the limited number of pregnant women requiring chemother-
apy, a strategy of monitoring, including clinical cardiac assessment
and echocardiographic functional evaluation, before starting
chemotherapy and re-evaluation before every dose should be
considered.
The scarce existing data, which are mostly in vitro and experimen-
tal, suggest low placental transfer of cancer drugs, including anthra-
cyclines, with limited exposure of the foetus.224 However, it is not
clear whether even small concentrations of anthracyclines affect the
normal development of cardiomyocytes. The long-term case obser-
vation does not show significant long-term cardiotoxic effects in
children born of mothers treated with cancer therapy during
pregnancy.225
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3. Strategies for prevention and
attenuation of cardiovascular
complications of cancer therapy
3.1 Treatment options to prevent or
recover from cancer therapy–induced
myocardial dysfunction
3.1.1 Before cardiotoxic cancer treatment
The timing and selection of cardioprotection depends upon various
clinical variables. If baseline cardiotoxicity risk is high due to pre-
existing CVD, previous anthracycline-containing chemotherapy or
poorly controlled cardiovascular risk factors, then a very stringent
optimization of risk factor control has to be obtained and a prophy-
lactic cardioprotective medication regimen should be considered
(Table 13). Cancer patients with low baseline risk scheduled for
high total cumulative anthracycline doses (.250–300 mg/m2 doxo-
rubicin or equivalent) may also be considered for prophylactic car-
dioprotective medication. One small study randomized adults with
haematological malignancies scheduled for high-dose anthracycline
chemotherapy to enalapril and carvedilol at HF therapy doses vs.
normal care, starting cardiac drugs before the first cycle of chemo-
therapy. The decrease in LVEF observed in the control arm at the
6-month follow-up was prevented in patients receiving both cardi-
oprotective drugs.226Whether patients with a low baseline risk who
are treated with anthracyclines also profit from preventive treat-
ment with ACE inhibitors, ARBs or beta-blocker therapy remains
controversial, and no recommendation can be made at this time.
In a recent prospective, placebo-controlled trial in patients with
early breast cancer treated with anthracyclines, the ARB candesar-
tan, comparedwith placebo or beta-blocker therapy, attenuated the
decrease in LVEF but had no effect on GLS or cardiac biomarkers.227
In this trial, metoprolol did not prevent a chemotherapy-associated
decrease in LVEF. Similarly, neither the ACE inhibitor perindopril
nor the beta-blocker bisoprolol had any effect on cardiac remodel-
ling in trastuzumab-treated patients with early breast cancer,
although most of these patients were not pretreated with anthra-
cyclines and therefore were at a lower risk of cancer treatment–
associated cardiac side effects.228
Cancer patients with pre-existing clinical HF or significant LV dys-
function at baseline require specialist cardiology review, preferably in
a specialist cardio-oncology clinic, where available, and the risk vs. bene-
fit regarding selection of chemotherapy options should be discussed
with the oncology team.229–232Options include selection of an alterna-
tive non-cardiotoxic chemotherapy, anthracycline preparations with
lower cardiotoxicity (e.g. liposomal doxorubicin), reduced-dose sche-
dules and/or additional cardioprotective drugs (e.g. ACE inhibitors,
beta-blockers, aldosterone antagonists or dexrazoxane) (Table 13).
Dexrazoxane, an intracellular iron-chelating agent, prevents the re-
duction in LV function caused by doxorubicin and can therefore be
considered an alternative to doxorubicin in selected cases.233–239 In
aCochranemeta-analysis in adult patients with cancer treatedwith an-
thracyclines, dexrazoxane significantly reduced the risk of HF with no
evidence for a difference in efficacy rate, survival or occurrence of sec-
ondary malignancies between dexrazoxane and control groups.240
Other meta-analyses showed no differences in secondary malignan-
cies in children treated with dexrazoxane.241,242 Currently the
European license for dexrazoxane use is only for adults with advanced
or metastatic breast cancer who have received a cumulative dose of
.300 mg/m2 doxorubicin or .540 mg/m2 epirubicin and would
benefit from continued anthracycline-based therapy.243,244
3.1.2 Patients with troponin elevation
Initiation of cardioprotection may be considered in patients with
cancer who have a troponin increase during treatment with high-
dose anthracycline-containing chemotherapy regimens. A clinical
trial that randomized 114 patients who received high-dose chemo-
therapy and experienced an early (within 72 h after each cycle) in-
crease in troponin levels to enalapril vs. placebo showed a
significantly lower incidence of cardiac events, including HF and
asymptomatic LV dysfunction, after a follow-up of 12 months in
the group treated with enalapril.113
3.1.3 Patients with asymptomatic reduction in left
ventricular ejection fraction during or after cancer
treatment
LVEF reduction meeting the definition of cardiotoxicity may be con-
sidered as stage B HF (i.e. patients with structural heart disease but
no current or previous symptoms of HF), particularly if there is a
concomitant increase in natriuretic peptide. Depending upon the
magnitude of the decrease and the LVEF value, initiating one or
more guideline-based HF therapies should be considered.176,249
Table 13 Strategies to reduce chemotherapy-induced
cardiotoxicity226– 228,245 –248
Chemotherapy 
drug
Potential cardioprotective 
measure
All chemotherapy 
drugs
Identify and treat cardiovascular risk factors
Treat comorbidities (CAD, HF, PAD, HTN)
QTc prolongation and torsade de pointes:
- Avoid QT prolonging drugs
- Manage electrolyte abnormalities
Minimize cardiac irradiation
Anthracyclines and 
analogues
Limit cumulative dose (mg/m2):
- Daunorubicin <800
- Doxorubicin <360
- Epirubicin <720
- Mitoxantrone <160
- Idarubicin <150
Altered delivery systems (liposomal 
doxorubicin) or continuous infusions
Dexrazoxane as an alternative
ACE-Is or ARBs
β-blockers
Statins
Aerobic exercise
Trastuzumab ACE-Is
β-blockers
ACE ¼ angiotensin converting enzyme; ACE-I ¼ angiotensin converting
enzyme inhibitor; CAD ¼ coronary artery disease; HF ¼ heart failure; HTN ¼
hypertension; PAD ¼ peripheral artery disease; RCT ¼ randomized controlled
trial.
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One observational study evaluated the efficacy of enalapril and
carvedilol in patients with LVEF ≤45% detected following high-dose
anthracycline-based chemotherapy. Although there was no control
group, full LVEF recovery occurred in 42% of patients treated with
enalapril and carvedilol. Importantly, cardiac-specific treatment
within 6 months after the end of chemotherapy increased the like-
lihood of LV function recovery.38 In a longer-term study, optimal
HF therapy appeared to be associated with an improvement in LV
dysfunction noted after chemotherapy.36
3.1.4 Patients with asymptomatic reduction in global
longitudinal strain during chemotherapy
Currently there is no evidence to guide specific cardioprotection if
early signs of subclinical myocardial dysfunction are detected during
echocardiography-based GLS surveillance.85,90,250 GLS may be a
more sensitive tool to detect early cardiotoxicity, but based on cur-
rently available evidence, cancer treatment should not be stopped, in-
terrupted or reduced in dose based on a new GLS reduction alone.
3.1.5 Patients with heart failure during and following
cancer treatment
Cancer patients presenting with clinical HF during or following can-
cer treatment should be treated according to current ESC guide-
lines for HF.176,251 When presenting during chemotherapy,
referral to a cardio-oncology specialist service is preferable, and
close liaison with the oncology team is required to determine the
necessity and duration of any interruption of cancer treatment,
with interruption of cancer treatment recommended until the pa-
tient is clinically stable. Risk vs. benefit of further treatment with
the previous regimen will depend upon several clinical factors, in-
cluding the severity of LV dysfunction, clinical HF status, cancer
prognosis and efficacy of the cancer therapy.
If rechallenge with a drug having previously generated cardiotoxi-
city is planned, continuation with cardioprotective drug therapy
such as ACE inhibitors and beta-blockers is strongly recom-
mended.36,230 Other potential options include the selection of pre-
parations with a potentially less cardiotoxic profile (e.g. liposomal
doxorubicin251 – 253) or possibly other less cardiotoxic drugs
(e.g. dexrazoxane) when indicated (see section 3.1.1).240,254
3.1.6 Non-pharmacological interventions with a
cardioprotective effect in patients with cancer
Positive health-promoting behaviour, including lifestyle factors
(healthy diet, smoking cessation, regular exercise, weight control)
should be strongly advised. In particular, aerobic exercise is
considered a promising non-pharmacological strategy to prevent
and/or treat chemotherapy-induced cardiotoxicity. Walking and
cycling activities, even at significant levels of physical exercise,
have been tested, and the benefit was greater when the exercise
was more intensive, but not until exhaustion, which should be
strongly discouraged.255,256
Patients receiving cancer treatment often have multiple physical
and psychological adverse effects. A multidisciplinary approach is es-
sential for long-term management of patients with cancer.257 A re-
view of 56 trials involving 4826 participants showed an
improvement in quality of life and physical ability during and after
an exercise training programme (Table 14).258
3.2 Prevention of thromboembolic events
Chemotherapy increases the risk of VTE, a common cause of death
in ambulatory patients. Currently, primary prevention, mainly using
LMWH, should be proposed in high-risk ambulatory patients receiv-
ing chemotherapy (with multiple myeloma receiving anti-angiogenic
agents or locally advanced or metastatic pancreatic or lung cancers)
who do not have excessive bleeding risk.259–261
In patients hospitalized for cancer, several guidelines advocate the
use of thromboprophylaxis, although a recent meta-analysis of sub-
groups of trials including patients with cancer hospitalized for
medical conditions failed to find evidence of any global benefit or
risk of primary thromboprophylaxis.262 Studies are under way to
validate thromboprophylaxis based on risk factors and biomarkers.
Meanwhile, it is reasonable to consider thromboprophylaxis with
LMWH based on individual benefit–risk assessments.
For patients with central venous catheters, there is a reduction in
symptomatic deep vein thrombosis with the use of heparin and of
asymptomatic deep vein thrombosis with VKA compared with no
anticoagulation. However, heparins are associated with a higher
risk of thrombocytopaenia and asymptomatic deep vein thrombosis
compared with VKA, and therefore treatment decisions should be
individualized.263
3.3 Strategies for attenuation of
complications related to use of specific
agents
3.3.1 Anthracyclines
Several strategies can be used to prevent the LV dysfunction and HF
induced by anthracyclines while maintaining antineoplastic efficacy,
including reduction in the cumulative dose; use of continuous infu-
sions (up to 48–96 h) to decrease peak plasma levels in adult pa-
tients264 – 266; use of analogues (epirubicin, pixantrone)267 or
liposomal formulations, which are thought to have a lower risk of
cardiotoxicity and provide comparable antitumour efficacy or use
of dexrazoxane as a cardioprotectant.255,268–272 When there is evi-
dence of equal efficacy or superiority of non-anthracycline regi-
mens, they should be considered, particularly in patients with
established cardiovascular risk factors or previous exposure to
anthracyclines.87,273
Table 14 Summarizes the potential benefits of
exercise during and/or after cancer treatment
Improvement of:
• Cardiorespiratory and cardiovascular function
• Body composition (preservation or increase in muscle mass, loss of 
 fat mass)
• Immune function
• Chemotherapy completion rates
• 
• Body image, self-esteem and mood
Reduction in:
• Number and severity of side effects including nausea, fatigue and pain
• Reduction of hospitalization duration
• Reduction of stress, depression and anxiety
Muscle strength and flexibility
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Taxanes reduce doxorubicin elimination, resulting in higher plas-
ma levels,274 and promote its myocardial metabolism into more
toxic metabolites.275 Paclitaxel used in combination with anthracy-
clines enhances their cardiotoxicity.276 In this setting, paclitaxel is
more cardiotoxic than docetaxel. Thus it is recommended to ad-
minister anthracyclines before paclitaxel, separate the infusions
and/or limit the cumulative doxorubicin dose to 360 mg/m2.277 As
indicated above, the role of cardiac medications (ACE inhibitors,
ARBs and beta-blockers) for the prevention of anthracycline-
associated cardiac side effects in patients with normal cardiac
function and low risk before starting cancer treatment remains con-
troversial, and more data are needed.
3.3.2 HER2 targeted therapy
Co-administration of anthracyclines and trastuzumab markedly in-
creases the incidence of HF, but cardiotoxicity can be reduced sig-
nificantly by introducing a drug-free interval between the two
agents.277–281 In patients with metastatic disease who developed
HF, an association was observed between treatment with ACE inhi-
bitors and beta-blockers and LVEF recovery at 12 months, and a fur-
ther rechallenge with trastuzumab did not necessarily lead to
redevelopment of HF.282 Additionally, in patients with breast cancer
and normal LVEF before receiving trastuzumab and anthracycline
therapy, continuous use of beta-blockers reduces the incidence of
HF.37,38Whether this finding is also true for patients whowere trea-
ted predominately with non-anthracyclines before trastuzumab re-
mains controversial and no recommendation can be made.228 The
National Cancer Research Institute283 recommends that if LVEF de-
creases to,45% or.10 percentage points from baseline to a value
between 45% and 49%, trastuzumab should be interrupted and ACE
inhibitors should be started; trastuzumab may be reinitiated if the
LVEF is restored to .49%. If LVEF decreases below 50% but
.44%, trastuzumab may be continued but an ACE inhibitor should
be initiated. If the decrease occurs despite ACE inhibitor therapy,
the patient should be referred to a cardiologist, and preferably a
cardio-oncology service where available. In selected cases it may
be preferable to choose a beta-blocker rather than an ACE inhibi-
tor, depending on co-morbidities. The reversibility of LV dysfunc-
tion and the opportunity to resume administration of trastuzumab
after improvement in HF needs to be evaluated in a prompt manner,
and management should be individualized considering the each pa-
tient’s characteristics.37,85 Ongoing trials are evaluating the prophy-
lactic role of candesartan (NCT00459771), lisinopril –carvedilol
(NCT01009918) and perindopril –bisoprolol (NCT01016886)
combinations in reducing trastuzumab-induced cardiotoxicity.
The European Society for Medical Oncology guideline87 for pre-
vention of trastuzumab-induced cardiotoxicity recommends a delay
between completion of an anthracycline-based regimen and initi-
ation of trastuzumab, careful assessment of cardiac function before
starting and during follow-up and prophylaxis with ACE inhibitors
for the control of hypertension or new-onset LV dysfunction.
Regular aerobic exercise seems a promising strategy to attenuate
doxorubicin-induced LV dysfunction,284 but not trastuzumab-
induced cardiotoxicity.285
3.3.3 Pyrimidine analogues
In cancer patients with pre-existing CAD receiving drugs that may
produce myocardial ischaemia, aggressive control of CAD risk
factors (smoking, hypertension, diabetes, hyperlipidaemia) followed
by pharmacological treatment according to ESC guidelines286
should precede the administration of these drugs. Patients treated
with pyrimidine analogues frequently present angina pectoris,
ischaemia-related ECG abnormalities, arrhythmias and myocardial
infarction, even in patients with normal coronary arteries.120,287
Risk markedly increases in patients with a history of CAD, and since
prophylactic administration of nitrates and/or calcium channel
blockers may not be effective, pyrimidine analogues should be dis-
couraged in these patients.288–290 However, if an alternative ther-
apy is not available, close monitoring of the patient is advised.289
3.3.4 Vascular endothelial growth factor signalling
pathway inhibitors
Careful assessment of cardiovascular risk factors at baseline, close
blood pressure monitoring and discontinuation of drugs known to
raise blood pressure are essential to ensure prompt and aggressive
management of hypertension in patients treated with VEGF signal-
ling pathway inhibitors. Pharmacological strategies have been
reviewed (see section 2.5).
3.3.5 Radiotherapy
Heart-sparing radiotherapy techniques should be oriented towards
lowering the dose of radiation and the cardiac volume exposed
[from regional radiotherapy to involved field or involved node
radiotherapy (e.g. in Hodgkin lymphoma)].291 These results may
be reached using modern techniques based on 3D treatment plan-
ning with a dose–volume histogram and virtual simulation pro-
grammes.292,293 Using CT or magnetic resonance imaging,
powerful software systems are able to precisely delineate the con-
tours of the cancer and to guide delivery of radiation. To reduce the
cardiac radiation dose during radiotherapy, the following techniques
and strategies have been described:
† The deep inspiration breath-hold technique, or respiratory gat-
ing, allowing shielding of the heart from tangential fields and re-
duction of radiation to organs at risk without compromising
clinical target volume.294
† Multiple or rotational sources of radiation beams (photons/
electrons).
† Linear accelerator photons allowing treatment of patients with
equal weighting of anterior and posterior portals, with subcarinal
block and the shrinking field technique.
† Intensity-modulated radiation beams using multileaf collimators
are superior to partial shielding.
† Reporting and minimization of radiation doses received by
normal tissue.295
† Tracking systems, consisting of a small linear particle accelerator
mounted on a general purpose industrial robot with a robotic
arm, allowing the energy to be directed at any part of the body
from any location. The robotic mounting through a complex im-
aging system and software allows very fast repositioning of the
source and adaptation of radiation delivery, according to patient
movement and cancer modification, with an accuracy of 0.5 mm.
This method of radiotherapy treatment resembles a surgical
treatment and is also called ‘radiosurgery’.295
† Planning of radiotherapy tominimize themaximal distance between
the anterior cardiac contour and posterior tangential field edges.
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† Supine voluntary deep inspiration breath-hold techniques reduced
whole heart and left anterior descending coronary artery radiation
doses for some patients with left-sided breast cancer.296
Despite adoption of these measures, irradiation of the heart is
unavoidable when the target volume is close, such as in left breast
cancer and some cases of Hodgkin lymphoma.
4. Long-term surveillance
programmes for cancer survivors
The population of patients surviving for long periods after the diag-
nosis and treatment of cancer has substantially increased over the
past decade.297,298 It is imperative to raise awareness of possible car-
diac disease among cancer survivors as well as to provide appropri-
ate follow-up of such patients in clinical practice. Patients should be
informed of their increased risk of CVD at the outset of their
chemotherapy and should be advised and supported tomake appro-
priate lifestyle modifications. They should also be instructed to
promptly report early signs and symptoms of CVD.
Depending on the cancer and the treatment, a range of cardiovas-
cular complications can arise. For the purposes of clarity, only the
most common will be discussed here, but a strategy to screen for
important cardiovascular conditions will be outlined. In general,
the cardiovascular concerns can be summarized in categories
related to myocardial dysfunction, vascular disease and VHD.
4.1 Myocardial dysfunction
Both paediatric and adult survivors of anthracycline-based chemo-
therapy have a lifelong risk for the development of LV dysfunction
and HF.10,34,299 The time lapse between treatment and the develop-
ment of HF can be very long (.10 years).300 Thus, even in asymp-
tomatic patients treated with cardiotoxic therapy, particularly
anthracyclines, LV dysfunction and HF can potentially occur. Period-
ic screening with cardiac imaging and biomarkers, such as BNP,
should be considered in survivors, particularly those treated with
high cumulative doses or who demonstrated reversible LV dysfunc-
tion during cancer treatment.113,301 Any symptom suggestive of HF
should be similarly investigated, as many intercurrent illnesses may
unmask reduced cardiac reserve in patients with previous anthracy-
cline exposure. Early discontinuation of cardioprotective HF ther-
apy is not recommended. Although clinical trial data are still
lacking, the recommendation of this Task Force is to continue HF
therapy indefinitely unless normal systolic LV function remains
stable after cessation of HF therapy and no further cancer therapy
is planned. Since trastuzumab-induced cardiac dysfunction is fre-
quently reversible, cessation of HF treatment after normalization
of LVEF may be considered for these patients.3
4.2 Vascular disease
Evaluation for CAD, ischaemia and vascular disease is recom-
mended in patients with a history of mediastinal radiation, even if
asymptomatic, starting 5 years post-treatment and then at least
every 5 years thereafter.302,303 At least one major study suggested
that important cardiac disease is silent in a high percentage of pa-
tients with cancer who received mediastinal radiation, and screening
for ischaemic heart disease is a recommended practice.304 Vascular
damage may be present in areas distant to the radiation field when
patients are also given chemotherapy in addition to radiotherapy.305
Owing to the increased risk of stroke in patients with previous neck
irradiation, ultrasound scanning of carotid arteries to rule out
the presence of subclinical atherosclerosis could be included for a
comprehensive cerebrovascular risk assessment.
4.3 Valvular disease
Radiation-induced VHD is an increasingly recognized entity occur-
ring late after mediastinal radiotherapy, with a median time to diag-
nosis of 22 years.306 A minority of patients have completely normal
functioning aortic valves at the 20-year follow-up. Childhood cancer
survivors have a higher than expected incidence of tricuspid regur-
gitation, and the explanation remains to be determined.307 Affected
survivors are often no longer under the care of a treating cancer
specialist at the time of VHD diagnosis and, strikingly, the diagnosis
of cancer or history of radiation therapy is often not mentioned in
the patients’ current medical records.308 The European Association
of Cardiovascular Imaging and the American Society of Echocardi-
ography (EACVI/ASE) recommend a focused yearly history and
physical examination with echocardiography in symptomatic pa-
tients.95 For asymptomatic patients, the EACVI/ASE consensus
document95 recommends a screening transthoracic echocardio-
gram at 10 years post-radiation and serial exams every 5 years there-
after. Transoesophageal echocardiography adds important
information, especially when significant calcification or fibrosis is
present and limits transthoracic image quality. In addition, 3D echo-
cardiography may be helpful in the evaluation of mitral valve morph-
ology. CMR may also be useful in those with suboptimal
echocardiography or discrepant results.309
5. Future perspectives and
research directions
Cardio-oncology is a field with many unmet needs and gaps in
knowledge to guide best practice.310 The barriers separating oncology
and cardiology are dissolving rapidly from both disciplines, because for
patients with cancer, cure is not enough. The number of long-term
survivors is increasing, with the focus on cardiac health becoming a pri-
ority. A close collaboration between oncologists and cardiologists is
already perceptible in several centres where a cardio-oncology team
is clearly identifiable. Some centres, called cardiac-oncology centres,
have developed a well-structured service that includes several health-
care professionals (nurses, doctors, cardiologists, imaging specialists,
oncologists, etc.) with expertise in this field.
Cardiologists have particular challenges and responsibilities in this
emerging interdisciplinary alliance. These include a careful initial
evaluation before starting potentially cardiotoxic chemotherapy
and optimal control of pre-existing cardiovascular risk factors,
followed by ongoing cardiac safety monitoring for early signs of car-
diovascular toxicity and timely implementation of preventive or
therapeutic measures.231,233 All of this coordinated activity is crucial
to reduce both the burden of potential cardiovascular complica-
tions as well as the number of patients disqualified from specific
cancer treatment because of emergent CVD.311,312 Oncologists
and haematologists are faced with uncertainty over whether to
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disqualify a patient from treatment due to baseline CVD, although
cancer therapy might be lifesaving, or administer treatment and
wait until signs of cardiac injury.313 The latter strategy requires reli-
able and sensitive methods for the early detection of cardiac tox-
icity, which still remain to be defined, and effective strategies to
mitigate potential cardiac injury.85 Indeed, there is an urgent need
for more validated data to optimally manage and support patients
at risk of cardiovascular complications and exacerbation of cardiac
disease during the course of cancer treatment.
One of the most important unresolved issues is the choice
between a primary vs. secondary prevention strategy.6 It is still
unclear whether primary prevention is only relevant in patients
at highest cardiovascular risk or when using therapy with a high
cardiotoxic potential. Data on the prevalence and severity of clin-
ically relevant cardiotoxicity are generally disease and treatment
specific and are lacking for many clinical situations. For instance,
a young patient with breast cancer without cardiovascular risk
factors is unlikely to benefit from primary prevention during
most breast cancer treatment, whereas an elderly patient with
lymphoma would likely benefit from cardioprotection during an-
thracycline therapy. Therefore, it is also unclear whether a
primary protection strategy is justified and cost effective in low-
risk populations. The existing evidence supporting cardiovascular
preventive strategies in cardio-oncology is only suggestive
and requires further validation.37,230,248,314 With the encouraging
trend of the steadily improving survival rate for childhood cancer
survivors, there is an increasing responsibility to identify patients
with adverse health outcomes related to past cancer treatments.
While primary prevention of cardiotoxicity is still in the research
domain, secondary prevention has already entered clinical practice
guidelines despite persistent unresolved questions.287 There is
some evidence that good control of common cardiovascular risk
factors at initiation of chemotherapy mitigates the cardiovascular
consequences of cancer treatment in patients with a history of
hypertension, diabetes and HF.83,117 Prospectively validated criteria
of early cardiotoxicity, which would be representative of late mor-
bidity and mortality, are needed. The sensitivity of the current ap-
proach based on serial assessment of LVEF is insufficient.304 The
combined biomarker and imaging approach also suffers from a set
of limitations.101 Several circulating biomarkers (troponin I and
BNP or NT-proBNP) have been identified as useful for the early de-
tection of myocardial dysfunction and overt HF related to cancer
therapies.88,89,113,315 However, conclusive data are needed to estab-
lish whether biomarkers reliably predict clinically relevant late con-
sequences of cancer treatment. The effect of interrupting cancer
therapy remains to be determined, but should not be taken lightly,
as there are examples in general of interruptions or incomplete
treatment courses having an adverse effect on optimal cancer treat-
ment outcomes.
All of these challenges call for further concerted research. At this
stage, large, properly designed comprehensive trials could provide
answers to several of the above questions. As an example, primary
prevention could be compared with careful observation in which
secondary prevention measures would be triggered by a reduction
in LVEF or a significant increase in a cardiac biomarker.302 Concomi-
tant biobanking of blood samples, not only for testing cardiac bio-
marker levels, but also for genetic and epigenetic characterization
of patients, could provide future means to differentiate patients
who are particularly susceptible or resistant to cardiotoxicity
from a specific cancer treatment.
A strategy that could better stratify risk would identify patients in
which primary prevention or secondary prevention would be the
most beneficial. To succeed, there is a need for
† Refining the predisposing factors for the development of CVD
related to cancer treatment,
† Evaluating the rate of subclinical LV dysfunction and its transition
to overt HF,
† Defining the most reliable cardiac monitoring approach and
† Determining the clinical effect and outcome (in terms of morbid-
ity and mortality) after cancer therapy.
All of these actions are in concert with the aims of the recently
launched EACVI/Heart Failure Association Cardiac Oncology
Toxicity (COT) registry.316
Comparing clinically relevant outcomes with genetic, epigenetic,
biomarker and imaging characteristics assessed at baseline and dur-
ing active cancer treatment could provide data that would allow the
construction of true evidence-based strategies and open a new era
in cardio-oncology. The medical, social, ethical and economic rele-
vance of such a trial would be convincing for public and European
granting agencies. One of the important goals of this position paper
is to catalyse such initiatives. The alliance between oncologists and
cardiologists should also act as a lobby for introducing the analysis of
early and late cardiovascular side effects of new cancer drugs into
clinical trials, especially for patients with childhood cancer who
are at increased risk of chronic medical problems concerning the
vascular system. Innovative pharmaceutical companies should rec-
ognize that the time when cardiovascular safety will determine
the choice of personalized cancer treatment, with all the economic
and marketing implications of such an approach, is just around the
corner.75
6. Appendix
Supplementary Table Most recent reviews and
meta-analyses on the incidence of hypertension with
major VEGF inhibitor treatment
Drug Number 
of 
studies 
included
Number 
of 
patients
Incidence 
of all 
grades of 
HTN, %
Incidence 
of stage 
3-4 HTN, 
%
Bevacizumab165 20 6754 23.6 7.9
Sunitinib167 13 4999 21.6 6.8
Sorafenib168 13 2492 15.3 4.4
Axitinib169 10 1908 40.1 13.1
Vandetanib170 11 3154 24.2 6.8
Regorafenib171 5 750 44.4 12.5
HTN ¼ hypertension; VEGF ¼ vascular endothelial growth factor.
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